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1. HER-2 
The Human Epidermal Growth Factor Receptor-2 (HER-2) is a 185 kDa 
transmembrane receptor tyrosine kinase. It belongs to the Epidermal Growth 
Factor Receptor family (EGFR family), also known as ErbB family because of the 
homology with the oncogene of the avian erythroblastosis virus (v-erbB). Besides 
HER-2, this family is composed of three more members: EGFR (HER-1), HER-3 
and HER-4 (Yarden and Sliwkowski, 2001). Dysregulation (mutations or 
overexpression) of ErbB members has been strongly related to the initiation and 
maintenance of several solid tumors (Yarden and Pines, 2012; Arteaga and 
Engelman, 2014). 
 
1.1 Role and function 
ErbB proteins are widely expressed in cells of mesodermal and ectodermal 
origins and they are functionally important for the development of many organs, 
including skin, brain, lungs and gastrointestinal system. Furthermore, the 
employment of knockout models for EGFR or HER-2 showed the relevance of 
these proteins for mammary morfogenesis (Yarden and Sliwkowski, 2001; 
Moasser, 2007).  
EGFR family receptors consist of an extracellular domain with two 
cysteine-rich regions, a transmembrane domain and an intracellular tyrosine 
kinase domain (Figure I). After the binding to the extracellular domain of a 
ligand, i.e. the Epidermal Growth Factor (EGF) family, an activating 
conformational change occurs in the receptor, promoting the interaction with a 
monomer of the same kind (homodimerization) or with another member of the 
ErbB family (heterodimerization). Coupling two monomers (heterodimers are 
preferred to homodimers) causes transphosphorylation of tyrosines in the 
intracellular domain and the engagement of specific effectors that activate signal 
transduction (Yarden and Sliwkowski, 2001; Moasser, 2007). The most activated 
cascades downstream to ErbB dimers are Ras- and Shc-activated mitogen-
activated protein kinase (MAPK), PI3K-AKT, JAK-STAT and PLC pathways 
(Yarden and Sliwkowski, 2001). 
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Figure I.  HER-2 structure and mutations. LD1 and LD2, ligand-binding 
regions; CR1 and CR2, cysteine-rich regions; TM, transmembrane domain; TK, 
tyrosine kinase domain; CT, carboxy-terminal tail. (A) Site of somatic mutations 
found in tumors arisen in mice transgenic for Neu. (B) Site of 16 deletion. (C) 
Site of NeuT mutation. (D) Site of mutations found in rare cases of human lung 
cancers (Moasser, 2007). 
 
The activation of HER receptors triggers a multi-layered signaling network 
(Figure II), whose specificity and potency depend on the composition of ligands 
(at least 12) and monomers (input layer), along with the variety of intracellular 
effectors and regulators (signal-processing layers). The physiological outputs 
consist of cell division, migration, adhesion, differentiation and apoptosis. 
Ligand-mediated receptor endocytosis allows the turning off of the signaling 
network (Yarden and Sliwkowski, 2001). 
HER-2 is the only member of the EGFR family with unknown ligands. It 
constitutively exists in the activated conformation and, among ErbB members, it 
has the strongest catalytic activity. Furthermore, it is considered as preferred 
partner of ligand-induced heterodimers and the complex between HER-2 and the 
catalytically inactive HER-3 is the most active signaling heterodimer of the family 
(Yarden and Pines, 2012).  
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Figure II. The ERbB signaling network.  
(A) The input layer is composed of ligands and combinations of HER monomers. 
(B) Intracellular effectors of many signaling pathways represent the signal-
processing layer. (C) Cellular processes (output layer) triggered by the signaling 
network (Yarden and Sliwkowski, 2001).  
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1.2 HER-2-driven transformation 
In 1984, HER-2 was first connected to cancer when Schechter and 
colleagues isolated from carcinogen-induced rat neuroblastomas its mutated 
ortholog, called NeuT (Schechter et al., 1984). Since then, numerous studies have 
been conducted to shed light into HER-2/Neu-driven transformation.  
NeuT transforming ability was attributed to a point mutation in the 
transmembrane domain. Other mutations (including a deletion), found in the 
juxtamembrane region of the extracellular domain, were associated to HER-
2/Neu-driven mammary tumorigenesis in in vitro and in vivo models (Figure I). 
 HER-2 tumorigenic ability in humans was mainly related to the 
overexpression of the wild-type form of the receptor (Moasser, 2007). Hence, 
HER-2 overexpression alone seems oncogenic in humans without the need of 
activating mutations as in Neu/HER-2 transgenic mice. However, in more recent 
studies somatic mutations of HER-2 were detected in human cancers with no 
HER-2 gene amplification by next-generation sequencing. In particular, missense 
mutations in the catalytic and extracellular domains or duplications/insertions in 
exon 20 were found in lung adenocarcinoma and lobular breast, bladder, gastric 
and endometrial cancers (Bose et al., 2013; Arteaga and Engelman, 2014). 
HER-2 overexpression, caused by gene amplification or transcriptional 
deregulation, was reported in human breast, gastric, esophageal, ovarian, 
endometrial and lung cancers (Arteaga and Engelman, 2014). It determines a high 
availability of catalytically activated HER-2 on cell surface, that can omo- or 
heterodimerize with other monomers and trigger a high-potent intracellular 
signaling. As already described, HER-2/HER-3 is the most active heterodimer 
among EGFR family. HER-3, that strongly activates the PI3K-AKT pathway, is 
always phosphorylated in human HER-2-positive breast cancer, that has been 
found highly dependent on this survival and anti-apoptotic cascade (Lee-Hoeflich 
et al., 2008; Chakrabarty et al., 2013). On the contrary, HER-2 directly activates 
MAPK proliferative cascade but not PI3K-AKT pathway. Hence, HER-3 is an 
important partner for HER-2 and the combination between these two monomers 
enhances cell survival and proliferation and avoids apoptosis in HER-2-driven 
cancers (Yarden and Pines, 2012; Arteaga and Engelman, 2014). 
Introduction 
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In addition, when coupled with other ErbB monomers, HER-2 increases 
ligand-binding affinity and delays the ligand-induced receptor endocytosis, 
prolonging signal transduction. Transforming ability of HER-2 can also be 
enhanced by its interaction with other cell surface receptors apart from ErbB 
members, e.g. the insulin-like growth factor 1 (IGF-1) and the hepatocyte growth 
factor, further extending the concept of multi-layered network previously 
described (Emde et al., 2012). 
Apart from full-length HER-2 overexpression, the investigation of HER-2-
driven transformation and the search for activating mutations in human HER-2-
positive breast cancers led to the identification of truncated forms and a splice 
variant of HER-2, described in next section.  
 
1.3 HER-2 isoforms 
Carboxy-terminal fragments of HER-2 (CTFs, also called p95HER-2) 
were identified in about 30% of human HER-2-positive breast cancers. They 
originate by proteolytic shedding of the extracellular domain of full-length HER-2 
or by traduction of HER-2 mRNA from internal initiation codons. p95HER-2 
fragments are able to homodimerize on cell membrane, leading to a much more 
rapid and acute signal transduction than that driven by HER-2-containing dimers. 
The presence of CTFs in human HER-2-positive breast tumors has been 
associated to a worse prognosis and to a higher risk of metastatic progression; 
furthermore, they showed Trastuzumab-resistance (Arribas et al., 2011). 
However, two recent studies connected CTF expression in human samples of 
HER-2-positive breast cancer to a good Trastuzumab response (Scaltriti et al., 
2014; Parra-Palau et al., 2014). 
Besides CTFs, Morancho and colleagues observed the existence of N-
terminal fragments (H2NTF) in 60% of human HER-2-positive breast cancers. 
The intracellular catalytic domain is absent in H2NTF, but it can interact with 
HER-2 and the other ErbB members, inhibiting their functions. Acting as 
dominant negative molecule, the presence of H2NTF has been related to a better 
prognosis (Morancho et al., 2013). 
In addition to the truncated isoforms of HER-2, a splice variant lacking 
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exon 16 (initially called HER2, here referred to as 16) was identified in 1998 
by Kwong and Hung in human cancer cell lines. The in-frame deletion is localized 
in the same region of the extracellular domain that is mutated in Neu/HER-2 
transgenic models (Figure I) (Kwong and Hung, 1998). Due to the loss of two 
cysteine residues in the juxtamembrane region, a conformational change in the 
extracellular domain of HER-2 occurs, promoting intermolecular disulfide bonds 
with other 16 monomers (Castiglioni et al., 2006).  
The formation of stable and costitutively active homodimers results in a 
stronger activation of the signal transduction. In particular, an increased activation 
of PI3K-AKT and MAPK pathways was observed in MCF-7 and MCF-10A 
transfected with 16 and compared with cells transfected with full-length HER-2 
(Mitra et al., 2009; Alajati et al., 2013). 
 Furthermore, three different studies correlated the oncogenic properties of 
16 isoform to Src  kinase activation. Mitra and colleagues identified Src kinase 
as a critical upstream effector of both PI3K-AKT and MAPK cascades in MCF-7 
transfected with 16, and they showed a physical interaction between 16 and Src 
on the cell membrane, assuming a 16-mediated Src activation. Phospho-Src was 
also detected in 44% of human 16-expressing breast tumors (Mitra et al., 2009). 
Confirming these findings, molecular studies on tumors arisen in a 16 transgenic 
model (see section 3.1.1) showed that 16 constitutively-activated homodimers 
were able to trigger a Src-mediated signal transduction (Marchini et al., 2011). 
The strong correlation between activated 16 dimers/monomers and phospho-Src 
was highlighted also by Castagnoli and colleagues both on a cell line derived from 
a tumor of a 16 transgenic mouse (Milan 6, also described in the Results of this 
thesis) and on human HER-2-positive breast tumors. However, they did not 
observe Src-dependent activation of PI3K-AKT and MAPK pathways (Castagnoli 
et al., 2014).  
Phenotypically, the high potency of signal transduction led by 16 
determined an increased proliferation and a decrease in the death of cells 
transfected with the splice variant of HER-2 (Castiglioni et al., 2006; Mitra et al., 
2009; Alajati et al., 2013). In migration and invasion assays, a higher ability of 
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16-expressing cells (MCF-7 or MCF-10A) in respect to HER-2-transfected cell 
lines was observed by Alajati and colleagues and by Mitra and co-workers. In 
particular, the latter group associated this metastatic potential to Src activation 
(Mitra et al., 2009; Alajati et al., 2013). 
In in vivo experiments, the subcutaneous or intramammary injection of 
16-transfected cells in immunodeficient mice revealed the tumorigenic ability of 
this HER-2 variant (Castiglioni et al., 2006; Alajati et al., 2013). In addition, 
Alajati and colleagues showed that the intramammary or intravenous 
administration of cells was able to induce metastasis formation in 66% and 71% 
of immunodeficient mice respectively (Alajati et al., 2013). 
16 isoform has been found as 8-10% of HER-2 transcript amount in half 
HER-2-positive breast cancer patients and in 90% of women with locally 
disseminated disease (Castiglioni et al., 2006; Mitra et al., 2009). 
In vitro resistance to Trastuzumab was observed in 16-expressing cells in 
the studies conducted by Castiglioni and Mitra (Castiglioni et al., 2006; Mitra et 
al., 2009). On the contrary, other authors, focusing on in vivo experiments, 
demonstrated Trastuzumab susceptibility of 16-expressing tumors. Alajati and 
colleagues injected 16-transfected human cell line MCF-10A in 
immunodeficient mice, while in the study conducted by Castagnoli and colleagues 
Trastuzumab was administered to mice carrying the splice variant of HER-2 and 
to mice that had previously received the intramammary injection of MILAN 6 
(Alajati et al., 2013; Castagnoli et al., 2014). In the latter study, a retrospective 
analysis showed that patients with primary human HER-2-positive breast cancer 
had a lower relapse rate, after treatment with Trastuzumab, if tumors coexpressed 
at high levels both 16 and phospho-Src (Castagnoli et al., 2014). 
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2. HER-2-positive breast cancer and approved 
therapies 
HER-2-positive breast cancer is characterized by overexpression of HER-
2, either through gene amplification (20% of breast cancers) or through 
transcriptional deregulation (5%) (Moasser, 2007; Arteaga and Engelman, 2014).  
HER-2 amplification is an early event in breast tumorigenesis and is maintained 
during progression to advanced disease (Moasser, 2007). In these patients, 
metastases are primarily detected in visceral organs, i.e. lungs and liver (Cadoo et 
al., 2013). Overall, women with this subtype of breast cancer have a worse 
prognosis (Moasser, 2007). 
 
2.1 Clinically approved anti-HER-2 agents 
Besides conventional therapies (surgery, radiotherapy and cytotoxic 
chemotherapy), the development of HER-2-targeted therapies improved overall 
response rates, time to progression and overall survival in HER-2-positive breast 
cancer patients (Singh et al., 2014). 
 Trastuzumab is a humanized immunoglobulin G1 antibody that binds to an 
epitope in juxtamembrane region IV of HER-2 (Table I). It is able to inhibit 
cleavage of HER-2 ectodomain (preventing the formation of CTF), uncouple 
ligand-independent HER-2 homodimers (partially inhibiting downstream 
signaling) and trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and 
adaptive immunity to HER-2 (Arteaga and Engelman, 2014). It is approved by 
FDA (Food and Drug Administration) and EMA (European Medicine Agency) 
and represents the standard of care for patients with early or advanced HER-2-
positive breast cancer (Emde et al., 2012).  
However, after Trastuzumab approval an increase in the incidence of brain 
metastases was observed in patients. The progressive high number of HER-2-
positive breast cancer patients with metastatic spread in the brain (up to half of 
women) has been attributed to the reduction in mortality, the effectiveness of 
Trastuzumab in killing metastatic cells in other organs and to its incapability to 
cross the blood-brain barrier (Palmieri et al., 2007; Giordano et al., 2014; Singh et 
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al., 2014). 
Three more anti-HER-2 drugs have been developed and approved for 
clinical treatment of patients that fail first-line therapy with Trastuzumab: 
Lapatinib, Pertuzumab and T-DM1 (Table I).  
Lapatinib is a HER-2/EGFR dual inhibitor. Thanks to its small size, it is 
able to reversibly compete with ATP for the ATP-binding site in the kinase 
domain of HER-2 and EGFR. As a result, it inhibits signal transduction 
downstream to HER-2, including PI3K-AKT and MAPK pathways (Arteaga and 
Engelman, 2014). To enhance clinical benefit, typical regimens for Trastuzumab 
resistant patients with advanced disease consist of Lapatinib administration in 
combination with capecitabine or Trastuzumab (Yan et al., 2014). 
Pertuzumab is a humanized monoclonal antibody that binds to subdomain 
II of the extracellular portion of HER-2. It is able to prevent ligand-dependent 
heterodimerization of HER-2 with other HER members, including the high potent 
HER-2/HER-3 dimer. As a result, inhibition of signaling pathways is observed 
(Arteaga and Engelman, 2014; Yan et al., 2014). Due to their different targeted 
epitopes on HER-2 extracellular domain, Trastuzumab and Pertuzumab 
combination has been approved for the treatment of HER-2-positive breast cancer 
(Arteaga and Engelman, 2014). 
Trastuzumab-derivative of maytansyne 1 (T-DM1) is an antibody-drug 
conjugate, approved in 2013 for the treatment of metastatic HER-2-positive breast 
cancer. A molecule of Trastuzumab and 3.5 molecules of the compound are linked 
together by a covalent non-reducible thioether bond. T-DM1 combines 
Trastuzumab mechanism of action to the cytotoxic microtubule-depolymerizing 
ability of DM1. Hence, after Trastuzumab-mediated HER-2 binding, the 
conjugate is internalized and degraded by lysosomes. Then, DM-1 is released in 
the cytoplasm, causing lysis of HER-2-positive cancer cells (Arteaga and 
Engelman, 2014; Yan et al., 2014). 
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Table I. Clinically approved anti-HER-2 agents (modified from Arteaga and 
Engelman, 2014) 
 
 
 
2.2 Resistance to current anti-HER-2 therapies 
Despite undeniable improvements in the treatment of patients, metastatic 
HER-2-positive breast cancer is still an incurable disease. Many patients display 
intrinsic (without initial response to treatment) or acquired (after an initial clinical 
response to the drug) resistance (Arteaga and Engelman, 2014).  
Among HER-2 isoforms, as described in section 1.3, CTF and 16 
expression in HER-2-positive breast cancer was connected to Trastuzumab 
intrinsic resistance, while H2NTF was related to a better prognosis in patients 
treated with the monoclonal antibody. However, further studies on 16 and 
p95HER-2 proposed a beneficial role of these isoforms in patients treated with 
Trastuzumab (Alajati et al., 2013; Castagnoli et al., 2014; Scaltriti et al., 2014; 
Parra-Palau et al., 2014). 
 Resistance to anti-HER-2 single-agent treatment was defined as “bypass 
track resistance” by Arteaga and Engelman (Arteaga and Engelman, 2014). In 
fact, the administration of a single drug is not sufficient to block the wide 
signaling network driven by ErbB receptors and the inhibition of a single receptor 
Drug Type of molecule Mechanism of action FDA approval
Trastuzumab humanized IgG1,  
binds 
juxtamembrane 
domain IV
inhibits ectodomain cleavage 
and ligand-independent HER-
2-containing dimers; ADCC 
and adaptive immunity to 
HER-2
1998 (metastatic breast) 
2006 (adjuvant early breast)        
2010 (advanced gastric)
Lapatinib small molecule reversible, ATP-competitive 
TKI
2006 (advanced breast)
Pertuzumab humanized IgG1, 
binds 
heterodimerization 
domain II
inhibits ligand-induced HER-
2-containing dimers
2012 (metastatic breast) 
2013 (neoadjuvant breast)
T-DM1 antibody-drug 
conjugate
same as Trastuzumab plus 
inhibition of microtubules and 
cell lysis (DM-1)
2013 (advanced breast)
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or pathway determine the activation of the others and the generation of feedback 
loops (Yarden and Pines, 2012; Arteaga and Engelman, 2014). Focusing on the 
input layer of ErbB network, Trastuzumab resistance was associated to increased 
levels of ErbB ligands, and activation of TGFβ receptors was involved in this 
mechanism (Ritter et al., 2007; Wang et al., 2008). Furthermore, IGF-1 
overexpression and dimerization with HER-2 cause resistance to Trastuzumab 
(Huang et al., 2010). In addition, incapability of anti HER-2 agents to inhibit 
HER-2 could be attributed to the downregulation of the receptor (detected in 
patients treated with Trastuzumab) or/and to the not uncommon clinical 
observation of heterogeneous tumors containing HER-2-positive and negative 
cells (Mittendorf et al., 2009; Arteaga and Engelman, 2014). 
Many mechanisms promoting anti-HER-2 resistance were detected in the 
signal-processing layer. Somatic mutations or amplifications in the PI3K-AKT 
pathway (PI3K, mTOR, PTEN) have been found in 30% of HER-2-positive breast 
tumors, conferring resistance to current treatments (Arteaga and Angelman, 
2014). Activity of Src kinase family members was also involved in HER-2 
inhibitors resistance, partially by phosphorylation and inhibition of the tumor 
suppressor PTEN and consequent constitutive activation of PI3K-AKT pathway 
(Zhang et al., 2011; Rexer et al., 2011). Furthermore, as described above, 
opposite results were obtained in the studies conducted by Mitra and Castagnoli 
regarding the role of 16/Src coexpression in HER-2-positive tumors and 
Trastuzumab resistance.  
Defects in apoptosis and cell-cycle control were also found in resistant 
cancers. High levels of Survivin, a caspases inhibitor, were detected in HER-2-
positive breast tumors resistant to Trastuzumab or Lapatinib. In addition, 
amplification of cyclin E and downregulation of the Cdk inhibitor p27
KIP1
 has 
been associated to Trastuzumab resistance (Arteaga and Engelman, 2014). 
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3. Preclinical models and experimental approaches 
targeting HER-2 
The study of breast cancer in humans is highly problematic for different 
reasons. First, early genetic events that lead to tumor formation are difficult to 
detect as they usually occur before the clinical presentation of the disease. In 
addition, comparisons among patients are hampered by the high heterogeneity of 
human breast tumors. Furthermore, early stages of the metastatic cascade are 
difficult to detect in patients for the low number of invasive cells involved in the 
process. 
Hence, the need to shed light on all cancer stages and to test new 
therapeutic strategies to overcome resistance to clinically approved therapies 
drove the development of preclinical models (Ottewell et al., 2006; Saxena and 
Christofori, 2013). 
 
3.1 Preclinical mouse models 
The use of mice as preclinical models relies on anatomical, physiological 
and genetic similarities. Besides, mice have a small size, are easy to breed and 
they have a short gestation time, as well as a relatively short life (Jonkers and 
Derksen, 2007).   
The ideal preclinical model of breast cancer should mimic the genetic and 
phenotypic changes that occur in patients. During the years, several mouse models 
have been developed, each of which is able only to partially reproduce the human 
situation. The most used preclinical models for the study of breast cancer are the 
genetically engineered mice (GEM) and transplantation models (Ottewell et al., 
2006).  
 GEM are developed to express (transgenic mice) or to lack (knockout 
mice) a gene of interest. They have been widely employed to study the early 
stages (initiation and progression) of many cancers but, due to the low incidence 
of metastases, they seem inappropriate for advanced disease studies (Ottewell et 
al., 2006; Saxena and Christofori, 2013). 
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Transplantation models consist of the injection of murine (syngeneic 
model) or human (xenogeneic model) cancer cells in mice. They are useful for 
studies on the various cancer stages as well as for the evaluation of new 
therapeutic approaches (Saxena and Christofori, 2013). 
 
3.1.1 HER-2 and 16 transgenic models 
The first genetically modified models developed for the study of HER-2-
positive breast cancer were transgenic for the rat homologue Neu, either the 
normal or the mutated form (NeuT) (Muller et al., 1988; Guy et al., 1992). 
Despite their usefulness in shedding light on HER-2/Neu driven transformation in 
breast cancer, they could not be used for the investigation of human HER-2-
targeted therapies.  
To overcome this issue, transgenic models for wild-type HER-2 were 
generated. The first model that successfully reproduced HER-2-positive 
mammary carcinogenesis in mice was developed by Finkle and colleagues in 
2004. In this model, also employed in the study described in this thesis and 
referred to as HER-2 model, overexpression of HER-2 in the mammary gland (but 
also in many other tissues) was achieved by the integration of 30-50 copies of the 
transgene on murine chromosome 6 under the promotion of the Murine Mammary 
Tumor Virus (MMTV). A tumor-free survival study was conducted on female 
transgenic mice with an endpoint of 52 weeks. 73% of mice developed 
asynchronous mammary tumors, with a mean latency of 36 weeks of age. 
Furthermore, lung metastases were detected in 40% of mice with tumors. As 
briefly described in section 1.2, the search for a transforming “second hit” on 
HER-2 proto-oncogene led to the identification of in-frame deletions, point 
mutations and insertions in more than 80% mammary tumors of mice 
overexpressing HER-2. These somatic mutations, as Neu mutations and splice 
deletion of exon 16, were localized in the cysteine-rich juxtamembrane region of 
HER-2. In a much lower extent, mutations were also found in the transmembrane 
domain of HER-2 (Finkle et al., 2004). 
The identification of 16 in human HER-2-positive breast tumors drove 
Marchini and colleagues in the generation of a preclinical model carrying this 
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HER-2 isoform under the promotion of MMTV (16HER2-LUC model, here 
referred to as 16 model and also described in the Results of this thesis) 
(Marchini et al., 2011). Firefly luciferase was included as reporter transgene to 
allow the bioluminescent visualization of 16 expression in murine tissues. The 
integration of only 5 copies of the transgene in murine chromosome 5 was 
sufficient to determine the exclusive mammary overexpression of 16. After just 
a mean latency of 15 weeks of age, a multiple asynchronous tumors spread in all 
virgin 16 females was observed (4-5 tumors/mouse were detected in animals 
between 12 and 19 weeks of age). Furthermore, at 25 weeks of age lung 
metastases were already present. All these findings, in addition to the absence of 
further transforming mutations on 16 gene, highlighted the high transforming 
and invasive ability of 16 (Marchini et al., 2011).  
 
3.1.2  Transplantation models 
The injection of murine cancer cells in an immunocompetent syngeneic 
mouse allows the study of the interactions among tumor, surrounding 
microenvironment and host immune responses. Cell lines can derive from 
spontaneous murine tumors or from carcinogen-, transgene- or gene knockout- 
induced tumors (Saxena and Christofori, 2013). According to the injection route 
(see below), the tumorigenic and/or the metastatic ability of different cell lines can 
be evaluated. Furthermore, susceptibility to new therapies (e.g. active or passive 
immunological strategies) in an immunocompetent host can be properly studied 
(Ottewell et al., 2006). 
Xenotransplantation  refers to the delivery/implantation of human cells or 
tissues into immunodeficient mice, in order to prevent an immune rejection by the 
host (Jonkers and Derksen, 2007; Saxena and Christofori, 2013). Xenograft 
models are relatively easy and cheap to generate, and allow the study of human 
tumor growth and metastasis development, as well as the effectiveness of 
therapeutic agents on human tumor cells or tissues (Ottewell et al., 2006). Many 
mouse strains carrying different gene mutations and therefore exhibiting various 
levels of immunodeficiency have been developed over the years, including nude 
and Rag
-/-
;Il2rg
-/-
 mice (Table II) (Thomsen et al., 2008).  
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In nude mice a single homozygous base deletion on Foxn1
nu
 gene in 
chromosome 11 determines a phenotype of hairlessness, athymia and T-cell 
deficiency (Hirasawa et al., 1998). Their partially compromised immune system 
allows the local growth of injected human cells, but it is not sufficient to promote 
the spread of metastases. Indeed, NK cells are able to kill circulating human 
tumor cells, complicating the study of tumor progression and invasion of distant 
organs (Naito et al., 1987).  
The search for new useful models led to the development of Rag2
-/-
;Il2rg
-/- 
mice. This immunodeficient strain is double knockout for the Recombination 
Activating gene 2 (Rag2) and for the Interleukin 2 Receptor Gamma chain gene 
(Il2rg) (Goldman et al., 1998). The homozygous mutation of Rag2, that usually 
participates in V(D)J recombination reaction for the formation of T cells receptors 
and B cells immunoglobulins, determines the absence of mature T and B cells in 
mice (Oettinger et al., 1990; Shinkai et al., 1992). Mice knockout for Il2rg gene, 
that encodes for the common gamma chain of IL-2, IL-4, IL-7, IL-9, IL-15 and 
IL-21 receptors, are defective in mature T and B cells and totally deficient in NK 
cells (Cao et al., 1995; Kovanen and Leonard, 2004). As a result, knockout mice 
for both genes are severely immunocompromised and prone to the growth of 
human cancer cells (Goldman et al., 1998). Furthermore, Nanni and colleagues 
showed the ability of this model in mimicking human metastatic spread (Nanni et 
al., 2010). 
Besides mice, the selection of the most appropriate cell line to be injected 
is an important issue in order to obtain a highly efficient preclinical model. To 
amplify the growing and invasive intrinsic ability of tumor cells, selection of 
increasingly aggressive variants is performed. For example, to select human breast 
cancer metastatic variants, Francia and colleagues injected MDA-MB-231 triple 
negative cells subcutaneously or intramammary in immunodeficient mice; then, 
metastatic colonies were isolated and cultured in vitro. Many consecutive in vivo-
in vitro stages were performed to obtain a highly metastatic cell line. The same 
group of scientists first developed a HER-2-positive breast cancer metastatic 
model, transducing MDA-MB-231 with HER-2 gene and selecting metastatic 
variants as described above (Francia et al., 2011).  
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The selection of tumor sublines can be usefully employed to obtain 
metastatic variants with a specific targeted organ. The use of these cell lines 
allows investigational studies on metastatic organ-tropism as well as on 
therapeutic strategies for the treatment of specific colonized organs (Saxena and 
Christofori, 2013). Focusing on breast cancer-induced brain metastases, in the 
studies conducted by Bos and Francia MDA-MB-231 sublines highly metastatic 
to the brain were selected (Bos et al., 2009; Francia et al., 2011). After 
transducing MDA-MB-231 and MCF-7 with HER-2 and selecting variants, 
Palmieri and colleagues developed a HER-2-positive metastatic model for brain 
metastases (Palmieri et al., 2007; Gril et al., 2011).  
Depending on the route of cancer cells delivery in syngeneic or 
xenogeneic mice, different aspects of tumor and metastatic processes of breast 
cancer can be evaluated. The subcutaneous (s.c.) injection of cells is a quick and 
easy tool to produce and monitor tumor growth, due to the high vascularization 
and convenient anatomical location of skin. On this model susceptibility to new 
localized strategies can be successfully evaluated (Ottewell et al., 2006). 
Unfortunately, this ectopic transplantation model fails to mimic advanced breast 
cancer, i.e. the development of metastases (Saxena and Christofori, 2013).  
Orthotopic injection of a breast cancer cell line into the organ from which 
cells were isolated (intramammary, i.ma.), allows to better mimic all aspects of 
breast cancer disease, including tumor histology, vascularity, tumor-stroma 
interaction, gene expression profiles and spontaneous metastases development. 
However, the metastatic spread has a relative high latency, and primary tumor 
resection could be required to observe advanced disease in mice (Ottewell et al., 
2006; Saxena and Christofori, 2013). 
For studies focused on late phases of the metastatic process, as well as for 
the development of anti-metastatic strategies, tumor cells are injected directly into 
the systemic circulation, allowing a rapid development of induced metastases. 
According to the injection site, metastases in different organs can be observed. 
The administration of cells in the lateral tail vein (intravenous injection) is the 
most common way to obtain induced metastases. The first colonized organ are the 
lungs, with further metastases to other organs, including the brain. Intracarotid 
Introduction 
23 
 
and intracardiac injections allow the development of metastases in the brain 
bypassing the pulmonary circulation. The latter route is also able to cause the 
growth of metastatic colonies in liver, ovaries, adrenal glands and bones. Finally, 
after intraportal and intrasplenic injection liver metastases are observed. A 
particular systemic delivery consists of the intraperitoneal injection of tumor cells, 
that causes local invasion (Khanna and Hunter, 2005; Ottewell et al., 2006; 
Saxena and Christofori, 2013; Daphu et al., 2013). 
 
Table II. Immunodeficient mouse strains developed for xenotransplantation 
(modified from Thomsen et al., 2008). 
 
 
 
 
 
 
Mouse strain Characteristics
Nude Thymic agenesis
XID Defect B cells signaling
Beige Defect in lysosomal trafficking regulator gene
NOD Interaction between several genes important for antigen 
presentation and T cells function
SCID DNA repair defect, V(D)J recombination defect
c
null Lack of receptors for IL-2, IL-4, IL-7, IL-9 and IL-15
b2M
null No expression of MHC class I due to lack of b-2-
microglobulin
Pfp
null No production of perforin in lytic granules
Rag1
null Inability to form V(D)J recombination, lack of B and T cell 
receptor
Beige /Nude /XID Combined effect of bg, nude  and xid mutations
SCID/Beige Combined effect of scid and bg mutations
NOD/SCID V(D)J recombination defect added to NOD anomalies
NOD/SCID/b2M
null V(D)J recombination defect, no MHC class I. Various 
NOD anomalies
NOD/Rag1
null No V(D)J recombination and NOD defects
NOD/SCID/c
null
Combined effect of SCID and c
null 
on NOD background
NOD/Rag1
null
Pfp
null No V(D)J recombination or perforin production and NOD 
defects
Rag2
-/-
;Il2rg
-/- Lack of  B, T and NK cells
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3.2 Experimental approaches targeting HER-2 
Due to the complexity of ErbB network and the high incidence of 
resistance to current anti-HER-2 agents, new therapeutic strategies targeting HER-
2 are required. 
In addition to the formulation of new anti HER-2 biological agents and 
chemical compounds, relatively recent approaches targeting HER-2 include 
cancer virotherapy (HER-2 retargeted viruses) and cancer immunoprevention and 
immunotherapy (anti-HER-2 vaccines) (Campadelli-Fiume et al., 2011; Lollini et 
al., 2011).  
 
3.2.1 Drugs 
Treatment of HER-2-positive breast cancer with a single anti-HER-2 agent 
does not potently suppress HER-2 signaling. A strategy to overcome “bypass 
track resistance” consists of combining multiple anti-HER-2 drugs at the same 
time. As described in section 2.1, dual HER-2 inhibition has been already 
approved for Trastuzumab in combination with Lapatinib or Pertuzumab, but 
other combinatorial regimens are under study in on-going clinical trials. In these 
studies HER-2 targeted agents are also combined with other biological therapies 
or with chemotherapy. Furthermore, besides dual inhibition of HER-2, some trials 
include a third drug (Table III) (Yan et al., 2014; Arteaga and Engelman, 2014).  
Besides combinatorial regimens, the efficacy of several new drugs 
targeting HER-2 is currently investigated in clinical trials, including that of 
Neratinib (a dual irreversible inhibitor of HER-2/EGFR), Margetuximab (a 
chimeric anti-HER-2 monoclonal antibody with a Fc domain optimized for 
ADCC), LJM716 (a neutralizing antibody against HER-3 in order to block HER-
2/HER-3 dimer) and 
212
Pb-TCMC-Trastuzumab (an alpha particle releasing 
radioactive lead conjugated to Trastuzumab) (Table III) (Yan et al. 2014). 
Instead of targeting HER-2 receptor, new experimental molecules focus on 
the inhibition of its signaling network. Due to its hyper-activation in HER-2-
positive breast cancers, PI3K-AKT cascade is one of the main targets of this 
strategy. Many PI3K-AKT inhibitors are being developed and investigated, 
including NVP-BKM120 (Novartis), which has a demonstrated ability to cross the 
Introduction 
25 
 
blood-brain barrier. This small molecule compound, that competes for ATP 
binding, inhibits all four class I PI3K isoforms and is also active against the most 
common somatic PI3Kα mutations  (Maira et al., 2012; Saini et al., 2013).  
Similarly, MEK inhibitors, including UO126 (DuPont), are being studied 
in clinical trials. These kinase inhibitors specifically bind to a hydrophobic pocket 
adjacent to, but not overlapping with, the ATP-binding site (non-ATP competitive 
inhibitors) of MEK1, MEK2 or both isoforms. MEK inhibition allows the 
blocking of many upstream signaling pathways that converge to MAPK cascade, 
although many HER-2-positive breast cancers showed resistance to the treatment 
with only a MEK inhibitor because of PI3K cascade hyper-activation (Chappell et 
al., 2011). In addition, PI3K inhibition alone has been associated to enhanced 
HER signaling and acquired dependency on ERK (downstream to MEK) in HER-
2-positive breast tumors (Serra et al., 2011). Therefore, combined anti-MEK/anti-
PI3K regimens are under evaluation, as well as combinations that include 
intracellular signaling inhibitors and anti-HER-2 agents (Table III) (Saini et al., 
2013, Arteaga and Engelman, 2014). 
Focusing on Src suppression, Mitra and co-workers showed that Dasatinib, 
a small molecule that inhibits Src kinase family but also receptor tyrosine kinases, 
was able to suppress the growth, proliferation and invasion ability of HER-2 and 
16-expressing cell lines (Mitra et al., 2009). Zhang and colleagues detected a 
higher Src activation in a brain-seeking selected variant of BT-474 (BT-474.Br) if 
compared with the parental cell line and showed its important role in disrupting 
the blood-brain barrier and promoting brain metastases formation. In accordance 
with this findings, they demonstrated that the combinatorial regimen of small 
molecule Src inhibitor Saracatinib and HER-2-targeted Lapatinib was able to 
reduce HER-2-positive brain metastasis incidence and to increase overall survival 
of nude mice that had previously received the injection of  BT-474.Br (Zhang et 
al., 2013). 
 Among other experimental drugs targeting HER-2, agents inhibiting 
VEGF, Hsp90 and matrix metalloproteinases are currently investigated (Table III) 
(Emde et al., 2012; Hurvitz et al., 2013). 
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Table III. Experimental drugs targeting HER-2 in HER-2-positive breast 
cancer (modified from Yan et al., 2014; Arteaga and Engelman, 2014). 
 
 
 
3.2.2 Virotherapy 
Cancer virotherapy exploits virus ability to infect, replicate into and kill 
tumor cells (Lollini et al., 2009). Indeed, the observation that natural viral 
infections caused cancer regression led to the entry of viruses in cancer therapy.  
First pioneering studies were based on the notion that virus families have 
evolved specificities for different cell types, and this tissue-tropism can be 
exploited for therapeutic development (Miest and Cattaneo, 2014). However, the 
use of wild-type viruses was frequently associated to high toxicity (Campadelli-
Fiume et al., 2011). The advent of genetic engineering allowed to obtain less 
aggressive viruses, but the attenuation interfered with the viral therapeutic 
efficacy. Nowadays, viruses are engineered to have greater tumour specificity 
and/or efficacy than their parental strains. Viruses from nine different families are 
currently under evaluation in clinical trials: Adenoviridae, Picornaviridae, 
Herpesviridae, Paramyxoviridae, Parvoviridae, Reoviridae, Poxviridae, 
Retroviridae and Rhabdoviridae (Miest and Cattaneo, 2014). 
Therapy Regimen
anti-HER-2 Neratinib
Margetuximab
LJM716
212Pb-TCMC-Trastuzumab
T-DM1+Pertuzumab
Trastuzumab+Neratinib
Trastuzumab+LJM716
anti-signaling effectors MEK inhibitors (UO126)
PI3K inhibitors (BKM120)
Src inhibitors (Dasatinib)
other targets Hsp90, VEGF, matrix metalloproteinases inhibitors
Trastuzumab+erlotinib (EGFR tyrosine kinase inhibitor)
Trastuzumab+everolimus (mTOR inhibitor)
Lapatinib+bevacizumab (anti-VEGF-A monoclonal antibody)
T-DM1+PI3K inhibitor
Trastuzumab+ Pertuzumab+PI3K inhibitor
Trastuzumab+LJM716+PI3K inhibitor
anti-HER-2 + chemotherapy anti-HER-2 agents + capecitabine/ docetaxel/ 
gemcitabine/paclitaxel
anti-HER-2 + other biological 
therapies
Introduction 
27 
 
The first study on genetically modified Herperviridae, conducted by 
Martuza and colleagues in 1991, demonstrated the therapeutic ability of an 
attenuated  Herpes Simplex Virus type 1 (HSV-1) in human gliomas (Martuza et 
al., 1991). 
HSV, that is a DNA virus, is particularly appropriate as oncolytic virus for 
many reasons. First, it is a common pathogen in humans, causing a self-limiting 
disease. In worst cases, specific therapies are available (e.g. acyclovir). In 
addition, its large genome makes the virus suitable for genetic engineering and 
allows the insertion of heterologous genes. Finally, HSV envelope glycoproteins 
well tolerate modifications (Campadelli-Fiume et al., 2011). 
Three main strategies have been employed to generate oncolytic HSV: the 
conditional replication of the virus in tumor cells, the potentiation of anti-tumor 
activity by the insertion of cytokines genes in virus DNA, and the retargeting of 
HSV to tumor cells (Campadelli-Fiume et al, 2011). 
Focusing on the last strategy, retargeted oncolytic viruses were developed 
combining the notions that viruses use cell surface molecules to enter into cells 
and that there are tumors that express/overexpress specific receptors on cancer cell 
membrane (e.g. HER-2 overexpression in HER-2-positive breast cancer) (Lollini 
et al., 2009). In detail, the entry-fusion apparatus of HSV consists of four 
glycoproteins: gB and gC mediate virus attachment to glycosaminoglycans, while 
gD binds cell receptor nectin1 or HVEM (herpesvirus entry mediator), triggering 
the gH/gL- and gB-mediated virion-cell fusion (Campadelli-Fiume et al., 2011).  
In 2009 Menotti and colleagues were able to fully detarget a HSV-1 from 
nectin1 and HVEM and to retarget it to HER-2. The HER-2 retargeted virus 
(called R-LM249) was obtained by replacing the gD Ig-folded core (half of gD 
ectodomain) with another Ig-folded molecule, a single-chain antibody (scFv) 
against HER-2 (Figure III). The engineered gene also contained the Enhanced 
Green Fluorescent Protein (EGFP) sequence for an easy fluorescent imaging 
detection of the virus. R-LM249 entered into and lysed only HER-2-
overexpressing tumor cells (SK-OV-3, ovarian cancer cell line resistant to 
Trastuzumab), barely infecting MCF-7 (intermediate-low HER-2 expression, 
breast cancer). SJ-Rh4 (HER-2-negative rhabdomyosarcoma) was not infected by 
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the virus. In in vivo experiments, R-LM249 intratumor treatment succeed in 
slowing down tumor growth in nude mice bearing SK-OV-3 subcutaneous tumors 
(Menotti et al., 2009). 
 
 
Figure III. Tropism of Wild-type and HER-2 retargeted HSVs (Lollini et al., 
2009) 
 
3.2.3 Vaccines 
 Starting from the observation that immunodeficient mice are more 
susceptible to spontaneous or chemical carcinogenesis than wild-type mice, 
immunoprevention of non-infectious tumors has been widely studied. Antigen-
specific (i.e. vaccines or monoclonal antibodies) and non-antigen specific 
approaches (cytokines and immunostimolants) are investigated in preclinical and 
clinical studies to delay or prevent tumor onset and progression (Lollini et al., 
2011). 
 Active immunization with vaccines exploits the expression in tumors of 
specific antigens, called oncoantigens, that drive carcinogenesis (Lollini et al., 
2006). According to their localization, three classes of oncoantigens have been 
identified: class I includes cell surface molecules, while extracellular or 
intracellular oncoantigens belong to class II and III respectively (Lollini et al., 
2011). Thus, overexpressed HER-2 on breast cancer cells (class I oncoantigen) is 
the perfect target for vaccines construction (Lollini et al., 2013).  
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The ideal vaccine should activate humoral and cellular response against 
tumor and induce immunological memory. Furthermore, it should be safe, easy to 
develop and administer. Several formulations of vaccines targeting HER-2-
positive breast cancer have been tested in preclinical and clinical trials, including 
peptide-, protein- or DNA-based vaccines, as well as whole-tumor cell and 
dendritic cell vaccines (Milani et al., 2013). 
In the Laboratory of Immunology and Biology of Metastasis a cellular 
vaccine composed of three immunogenic stimuli was developed to prevent 
mammary carcinoma in mice transgenic for the mutated rat isoform of HER-2 
(BalbNeuT mice). The vaccine was composed of cells with a high expression of 
Neu (specific stimulus) and of two potent adjuvants: the allogeneic class I major 
histocompatibility complex molecules (MHC) of the cells and murine IL-12 (non-
antigen specific stimuli). The latter adjuvant was delivered i.p. (systemic 
administration) or vaccine cells were transfected with IL-12 genes to obtain a 
local release. IL-12 was chosen because of its potent activity as stimulant of T 
helper 1 anti-tumor response and because of its anti-angiogenic properties 
(Boggio et al., 1998). Vaccination was able to break tolerance towards Neu: at 
one year of age, all vaccinated mice were still tumor-free, while control mice had 
already developed mammary tumors (Nanni et al., 2001; De Giovanni et al., 
2004).  HER-2-Cell vaccine, described in the Results of this thesis (De Giovanni 
et al., 2014), was developed according to the notions acquired in these previous 
studies. 
Exploiting the same principle that drove them to the development of the 
cell vaccine, De Giovanni and co-workers showed the efficacy of a DNA vaccine 
in preventing carcinogenesis of BALBNeuT with a p53 knockout allele. The 
vaccine was composed of three plasmids encoding the extracellular/ 
transmembrane domain of Neu, IL-12 and allogeneic MHC respectively. 
Electroporation of animals was used as adjuvant stimulus,  to promote the opening 
of cell membrane pores and the entry of plasmids in cells (De Giovanni et al., 
2009). 
In 2010 Quaglino and colleagues compared the immunopreventive 
efficacy of four DNA vaccines against HER-2/Neu. Two plasmids encoded for the 
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fully rat or human extracellular and transmembrane domains, while HuRT (also 
described in the Results of this thesis as HURT-DNA vaccine) and RhuT were 
engineered as chimeric plasmids of HER-2 and Neu extracellular and 
transmembrane domains. HuRT encoded a protein with 390 NH2-terminal 
residues from extracellular HER-2 domain, while 299-COOH aminoacids derived 
from Neu. Almost symmetrically, Rhut plasmid encoded a protein with 410 NH2-
terminal aa from extracellular Neu and the remainder from HER-2. The 
intramuscular injection of both chimeric plasmids and the adjuvant 
electroporation were able to elicit a stronger immunopreventive response in wild-
type and HER-2/Neu transgenic mice if compared to non-chimeric vaccines 
(Quaglino et al., 2010). 
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1. Cells 
Five human cell lines were used in this thesis: BT-474, MDA-MB-453 
(HER-2-positive breast cancer), MDA-MB-231 (HER-2-negative breast cancer), 
SK-OV-3 (HER-2-positive ovarian cancer) and MCF-10A (epithelial breast tissue 
of a woman with fibrocystic disease). HER-2-positive cell lines were kindly given 
by Dr. Serenella Pupa (Istituto Nazionale dei Tumori, Milan, Italy). MDA-MB-
231 cell line was purchased from American Type Culture Collection (ATCC). For 
the experiments on MEK inhibition, MCF-10A and BT-474 were kindly provided 
by Prof. Yosef Yarden (Weizmann Institute of Science, Rehovot, Israel). Human 
tumor cells were routinely cultured in Roswell Park Memorial Institute 1640 
(RPMI 1640) medium supplemented with 10% heat-inactivated foetal bovine 
serum (FBS) (Life Technologies, Milan, Italy). MCF-10A were cultured in 
DMEM:F12 medium (Gibco BRL, Grand Island, NY, USA) supplemented with 
10 µg/ml insulin, 0.1 µg/ml cholera toxin, 0.5 µg/ml hydrocortisone, 5% heat-
inactivated horse serum (Gibco BRL) and 10 ng/ml Epidermal Growth Factor 
(EGF). 
To better visualize metastases in the multiorgan metastasis model, MDA-
MB-453 were transfected with a plasmid expressing Enhanced Green Fluorescent 
Protein (pEGFP-N1, Clontech, Mountain View, CA) using Lipofectamine 2000 
(Life Technologies). Stable transfectant were selected adding the G418 (Life 
Technologies) at a final concentration of 1000 µg/ml to the medium.  
Six mouse mammary tumor cell lines were employed in this project: 
MAMBO 89, MILAN 6, 143-VS, 302-IVD, 156-VS and 156-IS. They were 
established from spontaneous primary mammary carcinomas arisen in HER-2 
model (MAMBO 89), 16 model (MILAN 6) and F1 model (143-VS, 302-IVD, 
156-VS and 156-IS). MILAN 6 was obtained and stabilized by Dr. Serenella 
Pupa, the other cell lines were obtained in the Laboratory of Immunology and 
Biology of Metastasis. Murine cell lines were stabilized (excluded MAMBO 89) 
and cultured in MammoCult (StemCell Technologies, Canada) supplemented with 
1% FBS. MAMBO 89 cell line was stabilized in Dulbecco’s Modified Eagle 
Medium (DMEM; Life Technologies) +10% FBS, supplemented with Bovine 
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Pituitary Extract 30 μg/ml (BPE; BD Biosciences, USA) and MITO Serum 
Extender 1:200 (BD Biosciences).  
All mediums were supplemented with penicillin 100 U/ml and 
streptomycin 100 µg/ml (Sigma-Aldrich, Milan, Italy). All cell lines were 
maintained at 37°C in a humidified 5% CO2 atmosphere.  
For the maintenance culture, cells were washed with Phosphate Buffer 
Saline (PBS; Life Technologies) and harvested by trypsin (0.05%)-EDTA 
(0.002%) treatment (Life Technologies). Cell number and viability was 
determined through erythrosine dye exclusion (Sigma-Aldrich) and 
hemocytometer count. 
 
2. Mice 
FVB-huHER-2 mice (Finkle et al., 2004), here referred to as HER-2 
model, were obtained from Genentech Inc. (South San Francisco, CA, USA). This 
line carries in heterozygosis the human full-length normal HER-2 gene under the 
control of the Murine Mammary Tumor Virus (MMTV) promoter on a FVB 
background. HER-2 gene heterozygosis was maintained by crossing HER-2
+/-
 
male mice with non-transgenic FVB female mice (purchased from Charles River, 
Calco, Italy).  
Δ16-HER2-LUC (Marchini et al., 2011), here referred to as 16 model, 
were kindly given by Prof. Augusto Amici (University of Camerino, Italy). This 
line carries in heterozygosis the human splice variant 16 gene under the control 
of MMTV promoter on a FVB background. 16 gene heterozygosis was 
maintained as described above for HER-2 model.  
F1 mice, transgenic for both genes, were obtained in the Laboratory of 
Immunology and Biology of Metastasis by crossing 16 male mice with HER-2 
female mice. 
Transgenic mice were screened by routine genotyping with PCR analysis 
(Finkle et al., 2004; Marchini et al., 2011). 
Balb/c Rag2
-/-
;Il2rg
-/-
 breeders were kindly given by Drs. T. Nomura and 
M. Ito of the Central Institute for Experimental Animals (Kawasaki, Japan). Mice 
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were bred under sterile conditions and used for the experiments described here at 
10-20 weeks of age. This line is double knockout for the Recombination 
Activating gene 2 (Rag2) and for the Interleukin 2 Receptor Gamma chain gene 
(Il2rg) (Goldman et al., 1998). 
Athymic Crl:CD-1-Foxn1
nu/nu
 mice (referred to as nude mice) were 
purchased from Charles River and kept under sterile conditions.  
All animals were bred in the animal facility of the Laboratory of 
Immunology and Biology of Metastasis (Department of Specialistic, Diagnostic 
and Experimental Medicine, University of Bologna, Italy). Virgin female mice 
were used in the experiments. Experiments were authorized by the institutional 
review board of the University of Bologna and done according to Italian and 
European guidelines. 
 
3. HER-2 and 16 expression 
The expression of total HER-2 on cell surface was evaluated in tumors and 
cell lines from HER-2, 16 and F1 models and in BT-474 by indirect 
immunofluorescence and cytofluorimetric analysis. The expression of HER-2 and 
16 transcripts was investigated  in the same tumors and cell lines by Real-time 
PCR. 
 
3.1 Indirect immunofluorescence and cytofluorimetric 
analysis 
After necropsy, tumor masses were minced with scissors, incubated for 5 
minutes with trypsin and passed through a 70 µm cell strainer (Becton Dickinson, 
Bedford, MA, USA) to obtain a homogeneous cell suspension. Before the 
incubation with the primary antibody, tumor suspensions were incubated with 
anti-mouse CD16/CD32 clone 2.4G2 (1:100 dilution; PharMingen, San Diego, 
CA). Next, tumor and cell suspensions were incubated with anti-human HER-2 
clone MGR-2 primary antibody (1:100 dilution; Alexis Biochemical, Enzo Life 
Science, Lansen, Switzerland). Then, samples were incubated with the secondary 
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fluorescein-conjugated mouse monoclonal antibody (IgG AlexaFluor 488, 1:100 
dilution; Life Technologies). Fluorescence intensity was determined through flow 
cytometry (FACScan, Becton Dickinson). 
 
 3.2 Real-time PCR 
RNA was extracted using TRIzol protocol (“Total RNA Isolation 
Reagent”; Life Technologies). Tissue samples were first disrupted using a mortar 
and pestle and grinded to a fine powder in liquid nitrogen. The suspension was 
then transferred in appropriate tubes allowing liquid nitrogen to evaporate and 
then TRIzol was added  to extract total RNA following the protocol provided with 
the reagent. The concentration and purity of RNA was determined by measuring 
the absorbance at 260 and 280 nm in a spectrophotometer (Ultrospec 1100 pro, 
Biochron, England). 1 µg of total RNA was reverse transcribed in 30 µl solution 
containing Moloney Mouse Leucemia Virus-Reverse Transcriptase (MMLV-RT), 
Random Examers (2.5 µM), Rnase OUT (1.33 U/µl), BSA (Albumin, from bovin 
serum 0.5 µg/µl) and dNTP (0.5 µM). RNA was incubated at 42°C for 120 
minutes and then the reaction was stopped by heating at 95°C for 5 minutes. All 
reagents were purchased from Life Technologies. 
Gene expression was analyzed by Real-Time PCR using ABI Prism 5700 
sequence detection system (Applera, Milan, Italy) or Thermal Cycler CFX96 
(Bio-Rad Laboratories, USA). Initially cDNA were diluted 1: 3.2 with H2O, then 
1 µl of cDNA was amplified. For ABI Prism 5700 sequence detection system, 
SYBR Green Master Mix Reagent 1X (Applied Biosystem, Applera) was 
employed. A specific primer forward for each gene and a common primer reverse 
were used (Table IV for primers sequences). The steps of amplifications were: 
50°C for 2 minutes, 95°C for 10 minutes and then 40 cycles including 95°C for 15 
seconds and 60°C for 1 minute. A default melting curve program was used to 
obtain the dissociation curve for each gene. mRNA expression levels were 
normalized to GAPDH (human or mouse, Table IV), as endogenous reference 
gene.  
For Thermal Cycler CFX96, 1 μl of cDNA was amplified using 
SsoAdvanced SYBR Green Supermix 1X (Bio-Rad Laboratories). The steps of 
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amplification were: 95°C for 30 seconds and then 40 cycles including 5 seconds at 
95°C and 15 seconds at 60°C. A default melting curve program was used to obtain 
the dissociation curve for each gene. mRNA expression levels were normalized to 
GAPDH (human or mouse), as endogenous reference gene.  
All primers were used at a final concentration of 200 nM. For relative 
quantification, Ct method was used: CtHER-2/16= CtHER-2/16- CtGAPDH.  
 
Table IV. Primers sequences for HER-2, 16 (Mitra et al., 2009), mouse 
GAPDH and human GAPDH genes. 
 
 
 
4. Sensitivity to drugs in 3-D culture 
The sensitivity in vitro to anti HER-2 drugs was evaluated in cell lines 
derived from HER-2, 16 and F1 models and in BT-474 in 3-D culture (0.33% 
soft agar containing the drug). Trastuzumab, Lapatinib and Dasatinib were kindly 
given by Dr. Serenella Pupa, NVP-BKM120 was obtained from Novartis 
Institutes for BioMedical Research, Oncology (Basel, Switzerland).  Drugs were 
used at the following concentrations: Trastuzumab 10 µg/ml, Lapatinib 1 µM, 
Dasatinib 1µM, NVP-BKM120 1 µM and 0.1 µM.  
Cells were suspended in MammoCult + 1% FBS containing 0.33% agar 
(overlayer) and layered on a base of MammoCult + 1% FBS containing 0.5% agar 
(underlayer) on a Costar 24-well plate (Corning Life Sciences, USA). Drugs alone 
or in combination were added both to underlayer and to overlayer. Plates were 
maintained at 37°C in a humidified 7% CO2 atmosphere.  
Colony growth was monitored weekly and determined by counting at 
31.25X magnification with Diavert microscope (Leitz, Milan, Italy) after 2-3 
Gene Primer Sequence 5'-3'
HER-2 forward GTGTGGACCTGGATGACAAGGG
16 forward CACCCACTCCCCTCTGAC
HER-2/16 reverse GCTCCACCAGCTCCGTTTCCTG
mouse GAPDH forward GCTCACTGGCATGGCCTTC 
reverse CCTTCTTGATGTCATCATACTTGGC 
human GAPDH forward ATCAGCAATGCCTCCTGCAC
reverse TGGTCATGAGTCCTTCCACG
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weeks from seeding. BT-474 cells were seeded at 500 cells/well, the other cell 
lines at 10,000 cells/well. Drug’s efficacy was assessed as percentage of colonies 
grown over control in 1-6 independent experiments. 
 
5. MEK inhibition and signaling 
The experiments on MEK inhibition were performed in the Laboratory of 
Prof. Yosef Yarden (Department of Biological Regulation, Weizmann Institute of 
Science, Rehovot, Israel). BT-474 and MCF-10A cell lines (1-2x10
5
 cells) were 
seeded on Costar 6-well plates (Corning Life Sciences) in their medium. After 24-
48 hours cells were transfected with  siRNA or treated with UO126. 
For siRNA transfections, Oligofectamine (Life Technologies) and ON-
Target SMART (Dharmacon, Lafayette, CO) oligonucleotides were used. For cell 
transfection, protocols suggested by the manufacturers were followed. 36-60 
hours from siRNA transfection, cells were serum starved for 12 hours and then 
stimulated with Epidermal Growth Factor (EGF, 10 ng/ml) for 0-8 hours. Next, 
cell lysates were obtained by centrifugation and Western Blot was performed. 
For the treatment with UO126, cells were serum starved for 12 hours and 
then incubated for 1 hour with UO126 5µM. Next, cells were stimulated for 0-8 
hours with EGF, cell lysates were obtained and Western blot was performed.  
For Western Blot, proteins were separated on a 8% polyacrylamide gel and 
then transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories). 
After blocking with Tris-buffered saline containing Tween-20 (TBS-T) plus 5% 
non-fat dry milk, membranes were incubated overnight at 4°C with primary 
antibodies diluted in TBS-T containing BSA 1% and NaN3 0.5%. The following 
primary antibodies were used: anti-HER2/ErbB2 (D8F12) XP rabbit monoclonal 
antibody (1:1,000 dilution; 4290), anti-phospho-HER2/ErbB2 (Tyr1221/1222) 
(6B12) rabbit monoclonal antibody (1:1,000 dilution; 2243), anti-phospho-
MEK1/2 (Ser217/221) (41G9) rabbit monoclonal antibody (1:1,000 dilution, 
9154), anti-MEK1 (30C8) rabbit monoclonal antibody (1:1,000 dilution, 9146), 
anti-MEK2 (13E3) rabbit monoclonal antibody (1:1,000 dilution, 9147) (all from 
Cell Signaling Technology, Danvers, MA, USA), anti-phospho-ERK1/2 clone 
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MAPK-YT mouse monoclonal antibody (1:20,000 dilution, M8159; Sigma-
Aldrich). 
Protein presence was detected through the incubation with the respective 
horseradish peroxidase-labeled secondary antibodies (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) followed by chemiluminescent reaction (ECL reagent, 
Amersham Pharmacia Biotech, Buckinghamshire, UK).  
 
6. Viability tests 
For the evaluation of the cytotoxic effect of R-LM249 on human cell lines, 
8x10
3
 cells/well were seeded in 96 well plates and treated with R-LM249 (10 
pfu/cell). AlarmBlue assay was performed at 48, 96 and 144 hours from infection 
and plates were read at 570 and 600 nm with a Synergy HTTR-1 fluorometer 
(BioTek). 
For Trastuzumab sensitivity, cells were seeded at 5-10x10
3
 cells/well. The 
day after, cells were treated with 0.001-100 µg/ml Trastuzumab and after 72-120 
hours Cell Proliferation Reagent WST-1 (Roche Applied Science) was added to 
wells. After one hour samples absorbance at 450 nm and 630 nm was read on an 
ELISA plate reader (Tecan Systems, San Jose, CA, USA). 
 
7. Preclinical models 
7.1 Spontaneous carcinogenesis in transgenic models 
HER-2, 16 and F1 female mice were inspected weekly by palpation to 
investigate tumor incidence, latency and number of tumors per mouse 
(multiplicity). During inspection, diameters of the first tumors arisen in animals 
were measured with caliper to evaluate tumor dimensions (progressively growing 
masses ≥50 mm3 were scored as tumors). Tumor size was calculated as follows: 
π
6
(√a×b)
3
 
where a = maximal tumor diameter, b = maximal tumor diameter perpendicular to 
a. 
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At necropsy, samples of tumor masses were collected for further analyses 
(immunofluorescence or Real-time PCR, see section 3). Samples for molecular 
analyses were freezed in liquid nitrogen and stored at  -80°C.  
Lungs were perfused with black India ink (15% in water, Rotring) to 
outline metastases and fixed in a modified-Fekete’s solution (95.7% ethanol 96%, 
4.3% glacial acetic acid). Autochthonous lung metastases were counted using a 
dissection microscope. 
 
7.2 Syngeneic transplantation models and therapy 
In HER-2 model, MAMBO 89 or MILAN 6 (10
6
 cells) were injected in the 
mammary fat pad (intramammary, i.ma.) of 2-5 HER-2 mice per group (17-20 
weeks old) in 0.1 ml of PBS to obtain the development of spontaneous metastases. 
For the induction of experimental metastases, HER-2 mice (7-17 weeks old) 
received the intravenous injection (in a lateral tail vein, i.v.) of 10
5 
cells in 0.4 ml 
of PBS.   
For the therapy with Trastuzumab and Dasatinib, lung metastases were 
induced with 10
5
 and 10
6
 MILAN 6 and MAMBO 89 cells respectively, injected 
i.v. in 0.4 ml of PBS in FVB non-transgenic mice. 7 days after cell injection, mice 
were randomized into four groups (8 mice/group) and treatments started. Treated 
mice (two groups) received the intraperitoneous (i.p.) injection of 4 mg/Kg 
Trastuzumab twice a week or the daily administration per os of 50 mg/kg 
Dasatinib. Control mice received the i.p. injection of diluent NaCl solution 0.9% 
(control group for Trastuzumab therapy) or DMSO per os (control group for 
Dasatinib therapy). Mice were sacrificed 11 weeks (MILAN 6) or 13 weeks 
(MAMBO 89) after cell injection and lungs were weighed and stained (to count 
metastases). 
For Trastuzumab therapy of a F1 tumor, fragments of a F1 tumor were 
implanted in the fourth left mammary gland in 10-16 weeks old FVB non-
transgenic mice (n=10). Starting 7 days after tumor implantation, 5 mice received 
biweekly the i.p injection of Trastuzumab (4mg/kg) for four weeks, while control 
group received the administration of NaCl solution 0.9%. 
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7.3 Xenogeneic transplantation models and therapy 
7.3.1 NVP-BKM120 therapy and metastasis quantification 
NVP-BKM120 was formulated in 1-methyl-2-pyrrolidone (NMP)/poly-
ethylene glycol 300 (Fluka) (10/90, v/v). MDA-MB-453-EGFP was injected i.ma. 
(10
7
 cells) or i.v. (2x10
6
 cells) in groups of 5-9 Rag2
-/-
;Il2rg
-/-
 mice. Starting 7 
days (i.ma.) or 1 day (i.v.) after cell challenge, mice were treated daily with 50 
mg/kg NVP-BKM120 given per os. Control mice received vehicle alone. Mice 
received four drug administrations in the first week and five drug administrations 
in the following weeks (i.ma. injection=12 total weeks; i.v. injection=7 weeks). 
Mice were sacrificed at various times, depending on tumor and metastasis 
growth, and an accurate necropsy was performed. To detect fluorescent 
metastases, whole mice and dissected organs were carefully examined using a 
Lightools imaging system (Lightools Research, Encinitas, CA, USA).  Lungs 
were stained, then lungs and liver metastases were counted.  
Brain was minced with scissors and passed through a 70 µm cell strainer 
(Becton Dickinson) to obtain a homogeneous cell suspension. Bone marrow was 
flushed from both femurs in PBS and filtered through a 70 µm strainer. 
Suspensions were observed at a fluorescent inverted microscope (Leitz, Leica 
Microsystem, Wetzlar, Germany). Metastatic cells in brain and bone marrow were 
quantified with immunofluorescence followed by cytofluorimetric analysis and by 
Real-time PCR.  
To quantify the percentage of HER-2-positive MDA-MB-453-EGFP in 
brain and bone marrow, direct immunofluorescence and cytofluorimetric analysis 
were performed. A mouse monoclonal antibody against human HER-2 (clone Neu 
24.7, Becton Dickinson) labeled with phycoerythrin was used. Fluorescence 
intensity was determined through flow cytometry (FACScan, Becton Dickinson). 
To quantify the number of human cells in brain and bone marrow, Real-
time PCR was performed. Genomic DNA was extracted with 10 mM Tris-HCl 
buffer pH 8.3 containing 50 mM KCl, 2.5 mM MgCl2, 0.01% gelatin, 0.45% 
igepal, 0.45% tween 20 and 120 µg/ml proteinase K. Samples were incubated 
overnight at 56°C and then 30 minutes at 95°C to inactivate the proteinase K. All 
reagents were purchased from Sigma-Aldrich. After genomic DNA quantification 
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by spectrophotometer, samples were diluted to a final concentration of 100 ng/µl 
and Real-time PCR was performed. 
Primer and probe sequences were specific for a sequence of the α-satellite 
region of the human chromosome 17. They were derived from primers and probe 
sequences described in the study of Becker and colleagues (Becker et al., 2002), 
with the sole alteration that the probe carried the non-fluorescent quencher dye 
TAMRA at the 3’ end (Table V). A 100 ng aliquot of DNA per sample was 
amplified with 250 nM primers and 100 nM probe in a final volume of 25 µl of 
TaqMan Universal PCR Master Mix (Applied Biosystems). After an initial 
denaturation step at 95°C for 10 minutes, 45 cycles of amplification were 
performed (95°C for 30 seconds and 60°C for 1 minute) using a 5700 Sequence 
Detection System (Applied Biosystems). Threshold cycle (Ct) values of samples 
were interpolated in a standard curve in each PCR. It was constructed adding 
scalar amounts of MDA-MB-453 human cells to cells from the mouse whole 
brain. 
 
Table V. Primers and probe for the α-satellite region of the human 
chromosome 17 (modified from Becker et al., 2002). 
 
 
 
7.3.2 R-LM249 therapy and metastasis quantification 
For the local therapy with R-LM249 of HER-2-positive breast cancer, 
MDA-MB-453 and BT-474 (10
7
 cells) were injected subcutaneously (s.c.) in the 
right hind leg in 0.2 ml of PBS in Rag2
-/-
;Il2rg
-/-
 mice. Starting 3 days after cell 
injection, R-LM249 (2x10
7
 or 10
8
 pfu) was administered intratumorally (i.t.) once 
a week (for 10 weeks). Control mice received the i.t. injection of NaCl solution 
0.9%. Tumor volumes were measured with caliper as described in section 7.1. 
For the therapy of HER-2-positive metastatic breast cancer with R-LM249, 
MDA-MB-453 (2x10
6
 cells) were injected i.v. in Rag2
-/-
;Il2rg
-/-
 mice. R-LM249 
(10
8
 pfu) was administered i.p. in 4 weekly injections. The incidence of 
Primer Sequence 5'-3'
forward GGGATAATTTCAGCTGACTAAACAG
reverse AAACGTCCACTTGCAGATTCTAG
probe 6FAM-CACGTTTGAAACACTCTTTTTGCAGGATC-TAMRA
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macroscopic metastases was determined at necropsy. Brain, lungs and ovarian 
metastases were quantified by Real-time PCR. Brain and lungs suspensions were 
obtained as previously described in section 7.3.1, while ovaries were not passed 
through the cell strainer. Extraction, quantification and amplification of genomic 
DNA was obtained as in section 7.3.1. In addition, a standard curve composed of 
serial amounts of MDA-MB-453 cells added to fixed amounts of mouse cells was 
included. Ct values were interpolated in the standard curves of each PCR, 
obtaining the relative amount of human to mouse cells in each sample (human 
DNA relative units). 
For the induction of ovarian cancer peritoneal carcinomatosis, SK-OV-3 
(2x10
6
 cells) were injected i.p. in nude or Rag2
-/-
;Il2rg
-/-
 mice. Starting 3 days 
after cell administration, mice were treated with 2x10
7
 or 10
8
 pfu of R-LM249 
once a week (for five weeks). The distribution of R-LM249 was detected using 
the Lightools imaging system (Lightools Research). Intraperitoneal metastases 
were collected at necropsy and weighed.  
 
7.4 Immunoprevention 
7.4.1 Vaccine schedules 
HER-2-Cell vaccine was composed of human HER-2-positive ovarian 
cancer cells SK-OV-3 associated with exogenous administration of recombinant 
mouse IL-12, providing the specific (human HER-2) and the adjuvant 
(xenogeneic MHC and IL-12) stimuli. The proliferative ability of cells was 
blocked by mitomycin-C treatment (120 µg/ml, Sigma-Aldrich) for 45 minutes. 
Vaccine administration started when mice were 5-8 weeks old. Vaccination 
schedule was based on a 4-week cycle. In the first two weeks proliferation-
blocked cells (2x10
6
  in 0.4 ml of PBS) were injected i.p. biweekly, while in the 
third week IL-12 was administered i.p daily (50 ng/mouse in the first cycle, 100 
ng/mouse in the following cycles). IL-12 was diluted at a final concentration of 
0.5 µg/ml in a solution of mouse serum albumin (MSA, Sigma-Aldrich) 0.01% in 
PBS. Control mice were untreated or treated with vehicle alone (PBS). 
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HURT-DNA vaccine, derived from pVAX1 (Life Technologies), was 
developed by Quaglino and colleagues (Quaglino et al., 2010) and consisted of 
the chimeric human/rat HER-2 plasmid, encoding for a chimeric protein in which 
the first 390 extracellular NH2-terminal residues are from human HER-2 and the 
remaining extracellular and transmembrane residues from the rat homologue Neu. 
Large-scale production and purification of the plasmids were performed with 
EndoFree Plasmid Giga kits (QIAGEN, Valencia, CA, USA). Vaccine 
administration started when mice were 15-22 weeks old. Vaccination schedule 
was based on a 10-week schedule. In the first and third week anesthetized HER-2 
mice received two intramuscular injections in the tibial muscles of 50 µg of 
plasmid diluted to a final volume of 40 µl (20 µl in each muscle) per mouse in 
final concentrations of 0.9% NaCl and 6 mg/ml polyglutamate. After the 
injections, electroporation of tibial muscles was performed by two square wave, 
25-ms, 375 V/cm pulses generated with a T830 electroporator (BTX, San Diego, 
CA, USA). 
In the second week and in weeks 4-10 no vaccination was performed. 
Control group was treated with pVax1 empty vector. 
HER-2-Cell and HURT-DNA vaccinations were repeated for the entire life 
of mice. Mice were inspected weekly by palpation. Progressively growing masses 
larger than 0.3 cm in diameter were scored as tumors. Mice were killed when 
tumor diameter exceeded 1.7 cm. 
 
7.4.2 ELISA (Enzyme-Linked ImmunoSorbent Assay) 
For the quantification of anti-HER-2 antibodies, mice sera were collected 
periodically and stored frozen at -80°C. Thermo Scientific Immunoplate Nunc 
Maxisorp 96-well microplates (Cole-Parmer North America, Vernon Hills, CA, 
USA) were coated overnight with the extracellular domain of human HER-2 
protein (1 µg/ml, 100 µl/well). The day after, blocking and washing of wells were 
performed and mice sera at 1:250 to 1:500 dilutions were added. After 2 hours of 
incubation and plate washing, secondary goat anti-mouse immunoglobulin G 
(IgG)-peroxidase conjugate antibody (1:12,000 dilution; Calbiochem, San Diego, 
CA, USA) was added. Then, 100 µl of 3,3’,5,5’-tetramethylbenzidine peroxidase 
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substrate were added (Thermo Scientific). The reaction was stopped with 0.18 M 
sulfuric acid. The absorbance was measured at 450 and 620 nm with an ELISA 
microreader (Tecan Systems). In parallel, a standard curve (0.04-30ng/ml) with 
anti-human-HER-2 mouse monoclonal antibody clone 4D5 (Genentech) was run. 
 
7.4.3 MLTC (Mixed Lymphocyte Tumor Cell Culture) 
Evaluation of cell-mediated response after vaccination was assessed with 
MLTC. Mice were sacrificed after three vaccination cycles at least. Spleens  were 
collected from control and vaccinated mice and passed through a 40 µm strainer 
(Falcon, Oxnard, USA) to obtain a homogeneous cell suspension. Total 
splenocytes were cultured for six days alone or in presence of proliferation-
blocked  HER-2-positive mouse (MAMBO 89) or human (SK-OV-3) cells (at a 
10:1 lymphocyte/tumor cell ratio) in RPMI 1640 medium supplemented with 10% 
FBS and recombinant mouse IL-2 (20 U/ml). Next, culture supernatants were 
collected, and mouse IFN- was quantified by ELISA (R&D Systems, 
Minneapolis, MN, USA). 
  
7.4.4 Indirect immunofluorescence and cytofluorimetric analysis 
Ig isotypes analysis was performed using indirect immunofluorescence and 
cytofluorimetric analysis. MAMBO 89 and SK-OV-3 were incubated with sera 
from HURT-DNA vaccinated mice. Next, secondary fluorescein-conjugated 
monoclonal antibodies directed against Ig subclasses were added: anti-mouse 
IgG1 clone A85-1; anti-mouse IgG2a clone R19-15; anti-mouse IgG2b clone 
R12-3; anti-mouse IgG3 clone R4082; anti-mouse IgM clone R6-60.2. All of 
them were purchased from BD PharMingen. Total Ig were quantified using anti-
mouse IgG AlexaFluor 488 ( Life Technologies) as secondary antibody. 
 
7.4.5 HER-2 inhibition and signaling 
MAMBO 89 was treated for 5-60 minutes with a pool of sera from HURT-
DNA vaccinated mice and cell pellet lysis was performed. Cell pellets were 
resuspended in Novagen PhosphoSafe Extraction Reagent (EMD Millipore, 
Milan, Italy) plus protease inhibitor cocktail 100X (Sigma-Aldrich) and incubated 
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for 10 minutes at room temperature. To remove nuclei, samples were 
centrifugated for 15 minuti at 12,000 x g at 4°C. Protein concentration in the 
supernatants was determined by DC Protein Assay (Bio-Rad Laboratories) using 
BSA as standard protein and absorbance was measured at 750 nm with 
spectrophotometer (ULTROSPEC 1100 pro, BIOCHROM). Samples were 
resuspended in Laemli Sample Buffer 2x (Tris-HCl 62.5 mM pH 6.8, 25% 
glycerol, 2% SDS, 0.01% Bromophenol blue; Bio-Rad Laboratories) with 5% β-
Mercaptoethanol (Sigma-Aldrich) and denatured at 100°C for 10 minutes. 
For Western Blot, proteins were separated on a 8% polyacrylamide gel and 
then transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories). 
After blocking with PBS containing 0.1% tween 20 plus 5% non-fat dry milk for 
two hours at room temperature, membranes were incubated overnight at 4°C with 
primary antibodies diluted in blocking buffer. The following primary antibodies 
were used: anti-c-ErbB2/c-Neu (Ab3) mouse monoclonal antibody (3B5) (0.2 
µg/ml; Calbiochem/EMD Chemicals), anti-p-Neu (Tyr 1248)-R rabbit polyclonal 
antibody (0.2 µg/ml sc-12352-R; Santa Cruz Biotechnology), anti-AKT rabbit 
polyclonal antibody (1:1,000 dilution; 9272), anti-phospho-AKT (Ser473) (D9E) 
XP rabbit monoclonal antibody (1:1,000 dilution; 4060) (all from Cell Signaling 
Technology) and anti-actin rabbit antibody (1 µg/ml; Sigma Aldrich). Protein 
presence was detected through the incubation with the respective horseradish 
peroxidase-labeled secondary antibodies (Santa Cruz Biotechnology) followed by 
chemiluminescent reaction (LiteAblotplus, Euroclone, Milan, Italy). 
 
7.4.6 Xenogeneic transplantation model and passive immunization 
HER-2-positive cell line SK-OV-3 (2x10
6
 cells) were injected i.p. in Rag2
-
/-
;Il2rg
-/-
 mice. Mice were treated i.p. with 200 µl of pooled sera from mock mice 
(untreated or vaccinated with pVAX1) or from mice vaccinated with HURT-DNA 
at day 1, 3, 7 and 14. Mice were killed 5 weeks after cell injection. An accurate 
necropsy was performed and tumor masses in the peritoneum were collected and 
weighed to quantify the therapeutic efficacy of anti-HER-2 antibodies. 
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8. Statistical analysis 
Mantel-Haenszel’s test, Student’s t test, Fisher’s exact test and non-
parametric Wilcoxon’s rank sum test were used  to analyze and compare the data 
presented in this thesis. 
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1. F1 Model 
The aim of this project was the definition of the contribute of wild-type 
full-length HER-2 and of the splice variant 16 to mammary HER-2 positive 
carcinogenesis. For this purpose, three mouse models that spontaneously develop 
mammary tumors were studied: a mouse model transgenic for the wild-type and 
full-length HER-2 (FVB-huHER-2 mice, here referred to as HER-2 model), a 
mouse model transgenic for 16 isoform (FVB-d16HER-2 mice, here referred to 
as 16 model) and a hybrid mouse model transgenic for both genes (F1 model). 
HER-2 mice were obtained from Genentech Inc., South San Francisco, CA, USA 
and were described for the first time by Finkle and colleagues in 2004 (Finkle et 
al., 2004). 16 mice were developed and kindly provided by Prof. Augusto 
Amici, University of Camerino (Marchini et al., 2011). F1 model was first and 
originally obtained in the Laboratory of Immunology and Biology of Metastasis 
by crossing HER-2 female mice and 16 male mice to better mirror the human 
situation, where these isoforms coexist in half HER-2-positive mammary tumors 
(Castiglioni et al., 2006; Mitra et al., 2009).   
 
1.1 Carcinogenesis 
Tumor onset in female mice carrying 16  was significantly faster than 
that of HER-2 mice (Mantel-Haenszel’s test, p˂0.001) (Figure 1A). 100% of 16 
and F1 mice developed tumors within 32 and 33 weeks of age, with a median 
tumor-free survival of 17 and 16.5 weeks respectively. Tumors in HER-2 mice 
started to be palpable much later, with a median tumor-free survival of 46 weeks 
and 12% of tumor-free mice after more than 100 weeks of age. 
In addition to the earlier tumor onset, F1 and 16 mice showed a 
significantly higher number of mammary tumors per mouse if compared to HER-
2 mice (Student’s t test, p˂0.01 at least from the 4th week for F1 model, from the 
5
th
 week for 16 model) (Figure 1B). On average, at 26 weeks of age F1 model 
displayed 3.9±0.6 tumors and 16 model 3.2±0.4 tumors, while HER-2 mice were 
still tumor-free.  
Then, the growth of first tumors arisen in the three models was evaluated 
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over-time (Figure 1C). Tumors of both models carrying 16 grew much more 
slowly than those of HER-2 model (Student’s t test,  p<0.05 at least).  
Taken together, data on tumor onset and multiplicity showed the 
aggressiveness of 16, if compared with HER-2, in fostering mammary 
carcinogenesis. Nevertheless, this anticipation seems not to be correlated with a 
faster tumor growth as it could be expected. In fact, looking at the kinetic of the 
first tumor volume, the presence of 16 slowed down tumor growth. 
 
1.2 Metastasis 
The autochthonous metastatic spread in the lungs of F1, 16 and HER-2 
mice was evaluated (Figure 2). No significant differences among the models were 
observed: nearly half mice of each model developed metastases, with a median 
number of lung lesions of 1 for HER-2 and 16 models and of 0.5 for F1 model.  
To better assess the metastatic contribution of each HER-2 isoform, we 
studied the metastatic ability of two cell lines previously stabilized in vitro: a cell 
line obtained from a tumor arisen in a HER-2 mouse in the Laboratory of 
Immunology and Biology of Metastasis (MAMBO 89) and a cell line derived 
from a 16 tumor (MILAN 6, obtained in the Laboratory of Dr. Serenella Pupa, 
Istituto Tumori, Milan, Italy). Table 1 shows the expression of plasmatic HER-2 
protein and the expression of HER-2 and 16 transcripts in these cell lines (see 
section 1.3). MAMBO 89 and MILAN 6 were injected orthotopically (i.e. 
intramammary, i.ma) or intravenously (i.v.) in HER-2 mice (Table 2).  After i.ma. 
injection of MAMBO 89, half mice developed spontaneous metastases in the 
lungs, with a median of 2 lesions. Lung metastases were observed in all mice 
treated with MILAN 6 (median=6). 80% of HER-2 mice that had received the i.v. 
injection of MAMBO 89 developed induced metastases (median=2), while 
MILAN 6 i.v. injection caused a  metastatic spread in the lungs of all animals 
(median=58). Globally, a higher metastatic spread was detected after the injection 
of 16-expressing MILAN 6. 
Induced metastatic spread in the lungs was evaluated also in non-tolerant 
syngeneic FVB mice (Table 3). Both cell lines i.v. injected determined the 
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development of lung metastases in 100% of mice. The median number of lung 
lesions was 64 after the injection of MAMBO 89 and 211 after MILAN 6 
administration.  
 
1.3 HER-2 and 16 expression 
Protein expression level of total HER-2 was evaluated in HER-2, 16 and 
F1 tumors by Cytofluorimetry (Fig. 3A). A primary antibody that binds both 
HER-2 isoforms was used, because specific antibodies for each isoform have not 
been developed yet. HER-2 tumors displayed a significantly higher HER-2 level 
than those of models carrying 16 (Student’s t test, p˂0.0001). Tumors of HER-2 
mice had a median fluorescence intensity of 698 (range 120-2054), while 16 and 
F1 tumors showed a median expression of HER-2 of 233 (range 107-422) and 221 
(range 27-2053).  
The expression/coexistence of HER-2 and 16 transcripts in 41 F1 tumors 
was analysed by Real-time PCR, using specific primers for each isoform (Figure 
3B). 83% of F1 tumors (34/41) presented a high level of 16 and a low level of 
HER-2 as those of 16 mice, while only 5% of tumors (2/41) showed an 
expression of the isoforms that was comparable to that of HER-2 tumors (high 
HER-2, low 16). A high level of both isoforms (high HER-2, high 16) was 
observed in 7% of analysed tumors (3/41). Finally, 2 F1 tumors expressed a high 
level of HER-2 and an intermediate level of 16. 
Analysis of  HER-2 and 16 expression was extended to cell lines derived 
from the three models (Table 1). MAMBO 89 and MILAN 6 were previously 
described in section 1.2. Among cell lines that were obtained and in vitro 
stabilized from F1 tumors,  4 cell lines were chosen for drugs experiments (see 
section 2) because they were representative of the different expression levels of 
HER-2 and 16 observed in F1 tumors. One of these cell lines (143-VS) showed a 
high expression of HER-2 and a low expression of 16, while an opposite 
expression profile was observed in 156-VS and 156-IS (high 16, low HER-2). 
The last chosen cell line was representative of the group of  F1 tumors with a high 
expression of both isoforms.   
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2. Anti-cancer strategies against HER-2 
The main aim of this project was the evaluation of innovative anti-cancer 
strategies against HER-2-positive breast cancer. This kind of cancer has a bad 
prognosis if compared with other types of breast cancer. In addition, despite the 
therapeutic revolution after the development of Trastuzumab, nearly 70% of 
patients with metastatic breast cancer have intrinsic resistance to this HER-2 
targeted therapy and almost all of them become resistant over-time (Brufsky, 
2014). In light of that, new and efficacious treatments targeting HER-2, its 
isoforms and its signaling pathways are required. 
  
2.1 Drugs 
The therapeutic efficacy of already clinically approved or under 
experimentation  drugs was studied in vitro and in vivo in HER-2-positive breast 
cancer models. Susceptibility to the following drugs was analysed:  
- Trastuzumab (recombinant humanized monoclonal antibody that target the 
extracellular domain of HER-2); 
- Lapatinib (reversible kinase inhibitor that blocks the catalytic domain of HER-2 
and EGFR); 
- Dasatinib (kinase inhibitor directed against Src kinase); 
- NVP-BKM120 (PI3K inhibitor); 
- UO126 (dual MEK1/MEK2 inhibitor). 
  
2.1.1 Trastuzumab 
In vitro sensitivity to Trastuzumab (10 g/ml) was evaluated in cell lines 
derived from HER-2, 16 and F1 mice as percentage of grown colonies compared 
to the control in a 3-D culture (0.33% soft agar containing the drug) (Figure 4A).  
F1 cell lines with a high level of 16 were the most sensitive to Trastuzumab 
(156-VS=24% growth over control; 156-IS=46%), followed by MILAN 6 (57%). 
All cell lines with high HER-2 (MAMBO 89, 143-VS and 302-IVD) were 
resistant to Trastuzumab.  
The efficacy of Trastuzumab on high 16 tumors was confirmed in vivo on 
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a F1 tumor model (Figure 4B-C). Fragments of a F1-derived mammary tumor 
with a high expression of 16 were implanted in immunocompetent non-tolerant 
syngeneic mice (FVB mice). After 24 weeks of intraperitoneal (i.p.) treatment 
with Trastuzumab (4 mg/kg), tumor growth was not detectable in any treated 
mouse, while in 80% of untreated mice the tumor had significantly grown 
(Fisher’s exact test, p˂0.05).   
Therapeutic effectiveness of the humanized monoclonal antibody was also 
studied in a metastatic setting (Table 4). To better define the roles of HER-2 and 
16 in conditioning the drug response, MAMBO 89 and MILAN 6 were injected 
i.v. in FVB mice. The i.p. treatment with the drug (4 mg/kg) highly inhibited the 
growth of induced metastases expressing 16 (Student’s t test, p˂0.001). The 
inhibition was evident as reduction of lung weight (Table 4A) and as decreased 
median number of lung metastases (Table 4B). The treatment was significantly 
effective also in reducing HER-2 metastases, but in a lower extent (Student’s t 
test, p˂0.05). 
 
2.1.2 Lapatinib 
Lapatinib (1 M) effectively reduced the number of grown colonies of all 
cell lines analysed in 3-D experiments (Figure 5A). However, cell lines 
expressing 16 were more sensitive to Lapatinib than those expressing HER-2 
alone  (Student’s t test, p˂0.05). In fact, in MILAN 6, 302-IVD, 156-VS and 156-
IS a complete growth inhibition was observed, while in MAMBO 89 and 143-VS 
the percentages of grown colonies were 64% and 33% respectively. 
The activity of Lapatinib was tested also in combination with Trastuzumab 
(Figure 5B). The rationale of combining these anti-HER-2 drugs is the fact that 
they target different portions of HER-2 protein: Lapatinib is directed against the 
intracellular domain of HER-2, while Trastuzumab targets the extracellular 
domain of the protein. No additional inhibition was found comparing the effect of 
the combination Lapatinib-Trastuzumab with that of Lapatinib alone. 
 
2.1.3 Dasatinib 
Sensitivity to Dasatinib (1 M) alone or in combination with anti-HER-2 
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drugs (Trastuzumab and Lapatinib) was studied in vitro and in vivo.  
In 3-D culture all cell lines derived from HER-2, 16 and F1 models were 
sensitive to Dasatinib, but the effect of treatment was significantly higher in cell 
lines carrying 16 gene (MILAN 6, 143-VS and 302-IVD) than in MAMBO 89 
(Student’s t test, p˂0.001) (Figure 6). In detail, after treatment with the drug the 
percentage of growth in MAMBO 89 was 53% , while in 302-IVD grown colonies 
were only 17%. MILAN 6 and 143-VS were completely inhibited by Dasatinib. 
 Nearly the same significant differences among cell lines were obtained 
combining Dasatinib with Lapatinib or Trastuzumab (Student’s t test, p˂0.01 at 
least). The triple combination (Dasatinib+Lapatinib+Trastuzumab) confirmed 
what previously described (Student’s t test, p˂0.05 at least). 
Focusing on the different treatments in each cell line, in MILAN 6 and 
143-VS no additional effect was seen after combining drugs with Dasatinib 
compared to Dasatinib alone. In 302-IVD all combinations were significantly 
more effective than Dasatinib alone (Student’s t test, p˂0.05 at least). In MAMBO 
89, additional effects were observed combining Dasatinib with Lapatinib and in 
the triple combination of drugs (Student’s t test, p˂0.001). 
As partially described before for Trastuzumab (see section 2.1.1), 
inhibition of HER-2 and 16 metastases by Trastuzumab (4 mg/kg) and/or 
Dasatinib (50 mg/kg) was evaluated (Table 4). Therapeutic efficacy of 
Trastuzumab was already discussed (section 2.1.1). In vitro efficacy of Dasatinib 
was not confirmed in vivo. Treatment with Dasatinib did not reduce the quantity 
of lung metastases expressed both as lung weight (Table 4A) and as number of 
counted metastases  (Table 4B). Focusing on the combination of Dasatinib with 
Trastuzumab, a significant additional effect of Dasatinib in the reduction of 16 
metastases was noted if compared with the efficacy of Trastuzumab alone 
(Student’s t test, p˂0.01). 
 
2.1.4 NVP-BKM120 
In vitro sensitivity to NVP-BKM120 was studied in cell lines derived from 
HER-2, 16 and F1 tumors. All cell lines in 3-D culture showed a 100%  growth 
inhibition when treated with NVP-BKM120 at the concentration of 1 M.  After 
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treatment with a lower concentration (0.1 M), only MAMBO 89, 156-VS and 
156-IS were sensitive to NVP-BKM120 (Figure 7). 
Brain metastases have a high incidence in patients with HER-2-positive 
breast cancer. Hence, due to the demonstrated ability of NVP-BKM120 to 
penetrate the blood-brain barrier, drug’s activity on human HER-2-positive 
metastases in the brain and other organs was tested (Nanni et al., 2012). For this 
purpose a mouse model of multiorgan metastatic dissemination, previously 
developed in the Laboratory of Immunology and Biology of Metastasis, was 
employed. It consists of the orthotopic (i.ma.) or i.v. administration of human 
HER-2-positive cell lines in immunodeficient Rag2
-/-
;Il2rg
-/-
 mice. These mice 
have a dramatically impaired immune system because of the absence of mature T, 
B and NK cells. The metastatic pattern in Rag2
-/-
;Il2rg
-/-
 mice well reproduces the 
multiorgan metastatic situation displayed by advanced HER-2-positive breast 
cancer patients. In particular, the high incidence of brain metastases makes this 
model the perfect target for new therapeutic approaches. Human HER-2 positive 
breast cancer cell line MDA-MB-453 was injected i.ma. or i.v. in Rag2
-/-
;Il2rg
-/-
 
mice. To better detect and quantify the metastatic burden in mice, MDA-MB-453 
was transfected with Enhanced Green Fluorescent Protein (EGFP). Figure 8 
shows EGFP and HER-2 expression profiles of this cell line at cytofluorimetric 
analysis. Both routes (i.ma, 10
7
 cells; i.v., 2x10
6
 cells) determined a wide 
multiorgan metastatic pattern. Starting seven days (i.ma.) or one day (i.v.) after 
cell injection, mice were treated per os with NVP-BKM120 (50 mg/kg) for 7-12 
weeks. The therapeutic activity of the drug was evident in multiple organs, where 
a sizeable proportion of mice were noted to be metastasis-free (Figure 9). In the 
group of mice injected i.v., a strong and significant reduction in the incidence of 
metastases was observed in brain, femoral bone marrow and liver (Fisher’s exact 
test, p˂0.05 at least). Figure 10 shows representative pictures of the therapeutic 
effect of NVP-BKM120 in brain and lungs after exposure of organs to the 
fluorescent Lightools imaging system.  
Reduction of brain macro-metastases at necropsy was confirmed after 
quantification of induced metastatic cells by Real-time PCR and Cytofluorimetry. 
These technologies were specifically developed to detect and quantify micro-
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metastases not visible at fluorescent observation. Real-time was performed to 
misure the number of human cells using primers and probe specific for a -
satellite region on the human chromosome 17, while Cytofluorimetry was able to 
quantify the percentage of HER-2-positive cells in brain. Both analyses confirmed 
the strong reduction in the amount of brain metastases (more than 90%) after 
treatment with NVP-BKM120 (Student’s t test, p˂0.05) (Figure 11A-B). The 
metastatic pattern was quantified by Cytofluorimetry also in femoral bone marrow 
samples. In the group of mice treated with the drug, a 71% metastatic reduction 
was observed (Figure 11C). Quantification by visual count showed a significant 
decreased number of involved bones per mouse after treatment (inhibition of 
67%)  (Student’s t test, p˂0.05) (Figure 11 D). A reduction was observed also in 
kidney and adrenal glands (Figure 11E). Globally, NVP-BKM120 was able to 
significantly reduce the number of metastatic sites per mouse, with an inhibition 
percentage of 54% (Student’s t test, p˂0.05) (Figure 11F). 
 
2.1.5 MEK inhibition 
The inhibition of MEK (Ras/Raf/MEK/ERK cascade) was studied in 
collaboration with the Laboratory of Prof. Yosef Yarden (Department of 
Biological Regulation, Weizmann Institute of Science, Rehovot, Israel). The aim 
of the study was the detection of modifications at protein level of EGFR family 
receptors and their intracellular effectors after inhibiting MEK by siRNA or by 
treatment with UO126. A time course with Epidermal Growth Factor (EGF) was 
included in all the experiments. 
To detect possible differences between non-neoplastic and cancer cells, the 
study was conducted on a non-tumorigenic cell line (MCF-10A, derived from 
epithelial breast tissue of a woman with fibrocystic disease) and on a HER-2-
positive breast cancer cell line (BT-474).  
Knockdown of MEK was achieved by transfecting siRNA 
oligonucleotides against MEK1, MEK2 or both isoforms simultaneously in these 
cell lines. The main result after silencing MEK was an increase in HER-2 
activation both in non-neoplastic and in HER-2-positive breast cancer cells if 
compared with controls (Figure 12). In detail, an increase in p-HER-2 expression 
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was observed after transfection of MCF-10A with siRNA MEK2 and with the 
combination  siRNA MEK1 + siRNA MEK2 (Figure 12A). An higher amount of 
activated HER-2 was detected in BT-474 lysates after combining siRNA MEK1 
and siRNA MEK2 at the same time (Figure 12B). The similar function of MEK1 
and MEK2 may explain the fact that only the inhibition of both isoforms was able 
to effectively increase p-HER-2 expression in both cell lines. Furthermore, the 
absence of increase in activated HER-2 after knocking down MEK2 alone in BT-
474 could be caused by the more active signaling cascades in cancer cells if 
compared with non-neoplastic cells. 
Similarly to transfection, treatment of cell lines with UO126 increased 
HER-2 activation (Figure 13). Both cell lines, after dual MEK1/MEK2 inhibition, 
displayed a higher expression of p-HER-2 compared to controls. In addition to 
that, an increase in p-MEK1/2 was detected in cells treated for 1 hour with the 
drug if compared with control cells. UO126 inhibition of MEK1/MEK2 is 
noncompetitive with respect to ATP (Duncia et al., 1998), allowing MEK 
activation but blocking MEK-mediated ERK activation. 
 
2.2 Oncolytic virus R-LM249 
Oncolytic virotherapy exploits the ability of viruses to target and kill cells. 
HER-2 overexpression on breast cancer cells makes HER-2-positive mammary 
tumor the perfect target for anti-HER-2 viruses. In 2009 the group directed by 
Prof. Campadelli-Fiume (University of Bologna) retargeted a herpes simplex virus 
1 to HER-2, obtaining R-LM249 (Menotti et al., 2009). Susceptibility to this 
oncolytic virus was evaluated on breast and ovarian HER-2-positive models in the 
Laboratory of Immunology and Biology of Metastasis (Nanni et al., 2013). 
 
2.2.1 In vitro sensitivity 
Cytotoxicity to R-LM249 was firstly evaluated in vitro on three HER-2-
positive cancer cell lines: MDA-MB-453 and BT-474, that are breast cancer cell 
lines, and SK-OV-3, that is an ovary cancer cell line. As negative control, MDA-
MB-231 (low/negative HER-2 expression) was included in the experiment. After 
six days of treatment, all cell lines with high HER-2 expression were killed by R-
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LM249 (Figure 14A). Only a residual 10% viability was detected in BT-474 and 
SK-OV-3, but when these cells were cultured again they were unable to 
proliferate. R-LM249 effectiveness was compared to that of Trastuzumab (Figure 
14B). Among HER-2-positive cell lines, only BT-474 was sensitive to the 72 
hours-treatment with the monoclonal antibody, while MDA-MB-453 and SK-OV-
3 displayed resistance to the drug. Therefore R-LM249, but not Trastuzumab, was 
able to target and kill all HER-2-positive cell lines analysed. These data are even 
more relevant if we consider the high incidence of patients with Trastuzumab-
resistant HER-2-positive tumors. 
 
2.2.2 Therapy of localized HER-2-positive breast cancer 
After demonstrating the cytotoxic activity of R-LM249 on BT-474 and 
MDA-MB-453, in vivo therapy of localized disease was assessed after the 
subcutaneous (s.c.) injection of these cell lines (10
7
 cells) in Rag2
-/-
;Il2rg
-/-
 mice 
(Figure 15). Tumor growth was inhibited by both chosen doses of R-LM249 
(2x10
7
 and 10
8
 pfu). In detail, in groups of BT-474-injected mice intratumoral 
administration of the retargeted virus strongly reduced tumor volume ( Student’s t 
test, p˂0.05 at least from day 20 at the lower dose, from day 13 at the higher dose 
of R-LM249) (Figure 15A). 59 days after challenge with BT-474, the control 
group reached a mean tumor volume of 2.6±0.2 cm
3
, while mice treated with 
2x10
7
 pfu of R-LM249 showed a mean tumor volume of 0.5±0.2 cm
3
. The higher 
dose administration of the oncolytic virus almost avoided tumor growth 
(0.08±0.05 cm
3
). Also the s.c. injection of MDA-MB-453 significantly reduced 
tumor volume of R-LM249-treated mice (Student’s t test, p˂0.05 at least from day 
13 for both doses) (Figure 15B). In these mice the mean tumor volumes at 59 days 
from challenge with cells were 0.2±0.1 cm
3
 (2x10
7
 pfu) and 0.1±0.05 cm
3
 (10
8
 
pfu). Focusing on mice survival (Figure 15C-D), R-LM249 was able to 
significantly prolong mice lifetime (Mantel-Haenszel’s test, p˂0.01 for both cell 
lines and both doses of virus). After BT-474 challenge and 10 weeks of virus 
administration, treated mice had a median survival time of 139 (lower dose) and 
146 (higher dose) days, while control mice had a much shorter life expectancy (73 
days after cell injection) (Figure 15C). For MDA-MB-453 groups, mice receiving 
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the treatment survived nearly a month more than mice treated with vehicle 
(median survival days: Vehicle=98, R-LM249 2x10
7
=125, R-LM249 10
8
=132) 
(Figure 15D). Furthermore, at more than 150 days after challenge with cells, 20% 
of treated mice were still alive (apart from the group injected with BT-474 and 
treated with 2x10
7
 pfu of R-LM249). 
 
2.2.3 Therapy of disseminated HER-2-positive breast cancer 
To mimic the wide metastatic pattern in clinic, the multiorgan metastasic 
model of breast cancer (see section 2.1.4) was employed. MDA-MB-453 was 
preferred to BT-474 for its Trastuzumab resistance, as previously shown (see 
section 2.2.1). 2x10
6
 cells were injected i.v. in Rag2
-/-
;Il2rg
-/- 
mice. The  i.p. 
treatment for 4 weeks with R-LM249 (10
8
 pfu) determined the complete absence 
of ovarian macro-metastases (Fisher’s exact test, p˂0.0001) (Figure 16A). On the 
contrary, in all mice receiving the PBS-treatment ovarian lesions were found, 
showing the high efficacy of R-LM249 in inhibiting peritoneal HER-2 positive 
macroscopic metastases. These data were confirmed after quantification of human 
cells in mice ovaries by Real-time PCR (Figure 16B). As already described, this 
molecular assay consists of the amplification of α-satellite sequences on human 
chromosome 17 if human metastatic cells are present. Confirming what detected 
at necropsy, the micro-metastatic burden was widely reduced by the 
administration of the oncolytic virus (Student’s t and non-parametric Wilcoxon’s 
rank sum tests, p˂0.0005). R-LM249 activity was not experimented only on 
peritoneal metastases, but also on brain lesions, often found in patients with HER-
2-positive breast cancer and connected with Trastuzumab incapability to cross the 
blood-brain barrier. The oncolytic virus was effectively able to target and destroy 
HER-2-positive cells in the brain (Figure 16C-D).  MDA-MB-453 i.v. injected in 
Rag2
-/-
;Il2rg
-/-
 mice gave rise to brain metastases in 78% of non-treated animals, 
while after administration of R-LM249 only 30% of mice presented brain 
metastases (Figure 16C). A significant reduction was observed by Real-time 
quantification: only 1.9±0.8 human DNA relative units were detected in the brain 
of treated mice, while a metastatic brain burden of 4.1±1.3 human DNA relative 
units was quantified in the control group (Wilcoxon’s non-parametric rank sum 
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test, p˂0.05) (Figure 16D). These data highlight the potential high therapeutic 
ability of R-LM249 to fight brain metastases, that is currently the most 
problematic challenge in HER-2-positive breast cancer patients’ treatment. 
Despite the high effectiveness on ovarian and brain metastases, R-LM249 
was not able to reduce the incidence of lung metastases (Figure 16E). 
Furthermore, only a small reduction of human cells in the lungs of treated mice 
was found after molecular quantification (Figure 16F). 
 
2.2.4 Therapy of disseminated HER-2-positive ovarian cancer 
Intraperitoneal metastases are commonly found in patients with 
disseminated HER-2-positive ovarian cancer. For this reason, two models of 
peritoneal carcinosis were developed in the Laboratory of Immunology and 
Biology of Metastasis. The first model consisted of HER-2-positive ovarian 
cancer cell line SK-OV-3 injected i.p. (2x10
6
 cells) in athymic nude mice, while 
in the second one Rag2
-/-
;Il2rg
-/-
 mice were employed. 
Figure 17 shows the therapeutic ability of R-LM249 i.p. administered in 
nude mice (2x10
7
 pfu) after the i.p. challenge with SK-OV-3. Mice lifetime was 
widely prolonged by the treatment, with a median survival time that moved from 
103 (control group) to 440 days (R-LM249 group) (Mantel-Haenszel’s test, 
p˂0.05). Due to the slow growth of cells in nude mice, the experiment required a 
long observation period and most of treated mice died not because of peritoneal 
metastases, but when they reached their expected lifetime. 
To better assess the actual efficacy of R-LM249 on disseminated ovarian 
cancer, the second model that employ Rag2
-/-
;Il2rg
-/-
 mice was developed (Figure 
18). After i.p. injection of SK-OV-3, all control mice rapidly developed peritoneal 
carcinosis, allowing a precise quantification of metastases after only six weeks 
from challenge with cells. Furthermore, in most of control animals ascitic fluid in 
the peritoneum was present (71%). Hence, Rag2
-/-
;Il2rg
-/-
 mice confirmed their 
superiority in miming the clinic situation of patients if compared with nude mice. 
The i.p. administration of R-LM249 (10
8
 pfu) started 3 days after cells injection 
and determined a 40% reduction in the incidence of peritoneal masses (Figure 
18A). A high and significant decrease in tumor burden in the peritoneum was 
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observed (Figure 18B): the mean cumulative weight of peritoneal metastases in 
the group treated with the oncolytic virus was 60±38 mg, much lighter than that of 
control group (1164±284 mg) (Student’s t test, p˂0.01). In mice treated with the 
virus peritoneal ascites was not found (Fisher’s exact test, p˂0.05) (Figure 18C). 
 To underline the efficacy of R-LM249 on peritoneal metastases, 
representative pictures of control and treated mice were taken at necropsy (Figure 
19A-B). R-LM249 was engineered by Prof. Campadelli-Fiume and colleagues 
with the insertion of EGFP sequence, allowing the monitoring of intraperitoneal 
spread of the virus. With this purpose, SK-OV-3 was injected i.p. in Rag2
-/-
;Il2rg
-/-
 
mice and after 9 weeks mice were treated with the virus. R-LM249 was able to 
target and reach all visible human HER-2-positive intraperitoneal masses, while 
surrounding human HER-2-negative tissue was green fluorescence-free (Figure 
19C).  
 
2.3 Anti-HER-2 vaccines 
HER-2 is a tumor-associated antigen (oncoantigen) and an ideal 
immunotherapeutic target (Lollini et al., 2006). Therefore, among investigational 
options for HER-2-positive breast cancer, anti-HER-2 vaccines are currently 
studied. The immunopreventive activity of two vaccines was assessed in the 
Laboratory of Immunology and Biology of Metastasis: a xenogeneic whole-cell 
vaccine (called HER-2-Cell vaccine) and a DNA human/rat chimeric vaccine 
(called HURT-DNA vaccine) (De Giovanni et al., 2014). 
 
2.3.1 Immunoprevention of HER-2-positive breast cancer 
Both vaccines successfully delayed tumor onset in immunocompetent 
HER-2 mice (Mantel-Haenszel’s test, p˂0.05) (Figure 20A). At 60 weeks of age, 
57% of mice vaccinated with HER-2-Cell and 64% of mice that were receiving 
HURT-DNA were still tumor-free, while 87% of mock animals had already 
developed at least a mammary tumor. In HURT-DNA group this percentage was 
still stable after more than 80 weeks of age. 
Vaccinations were able to postpone not only tumor onset, but also the 
death of mice with tumors. Median latency from tumor onset to death was 16 and 
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14.5 weeks for HER-2-Cell and HURT-DNA vaccinated mice, while this range of 
time was nearly a month shorter for not vaccinated mice (11.5 weeks).  
Focusing on tumor multiplicity, at 70 weeks of age the mean number of 
tumors per mouse was 2.4±0.3 for mock group, whereas only 0.4±0.3 and 1.0±0.4 
tumors were arisen in HER-2-Cell and HURT-DNA groups respectively (Figure 
20B). Hence, the number of tumors per mouse was significantly reduced by 
vaccinations (Student’s t test, p˂0.05 at least from the 50th week in HER-2-Cell 
vaccinated group and from the 54
th
 week for HURT-DNA group). Globally, HER-
2-Cell and HURT-DNA vaccines were both able to delay tumor onset, prolong 
life expectancy and reduce the growth of multiple tumors in HER-2 mice. 
 
2.3.2 Immune responses to anti-HER-2 vaccines 
To understand the effect of vaccinations on the immune system, sera from 
mock and vaccinated groups were collected at different times and analysed by 
ELISA (Figure 21A). Both vaccines were able to break the tolerance towards 
HER-2 and induce the humoral response in HER-2 mice. However, HURT-DNA 
vaccine caused a stably higher production of anti-HER-2 antibodies if compared 
with HER-2-Cell vaccine (Wilcoxon’s non-parametric test, p˂0.05 at least at 4th, 
24
th
 and 40
th
 weeks of treatment). Specifically, at 4 and 12 weeks of vaccination 
the mean concentration of anti-HER-2 antibodies in sera of HURT-DNA group 
was nearly 20 µg/ml (week 4, 26.1±22.4 µg/ml; week 12, 19.0±14.5 µg/ml). At 
the following time points the antibodies level increased even more, reaching a 
mean concentration of 57.4±23.0 and 59.2±41.8 µg/ml at 24 and 40 weeks 
respectively. Focusing on the humoral response elicited by HER-2-Cell vaccine, 
anti-HER-2 antibodies reached the concentration peak of 4.5±1.1 µg/ml after 12 
weeks of vaccination, while nearly 1 µg/ml of anti-HER-2 antibodies was detected 
in sera of vaccinated mice at 4
th
, 24
th
 and 40
th
 weeks of treatment (week 4, 1.4±0.5 
µg/ml; week 24, 1.1±0.4 µg/ml; week 40, 0.9±0.3 µg/ml). 
Cell-mediated immune response was evaluated as murine Interferon- 
(IFN-) production by spleen cells of control and vaccinated mice (Figure 21B). 
Spleen cells were collected and cultured for six days alone (spontaneous release) 
or in co-culture with two HER-2-positive cell lines to foster the cytokine 
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production (MAMBO 89 and SK-OV-3). MAMBO 89 derived, as previously 
described (see section 1.2), from a mammary tumor of a HER-2 mouse and was 
employed as syngeneic cell line (syn-HER-2). SK-OV-3 (xenogeneic, xeno-HER-
2) was the main component of HER-2-Cell vaccine. After culture, supernatants 
were collected and ELISA was performed. Spleen cells of HER-2-Cell vaccinated 
mice spontaneously produced IFN-. The presence of MAMBO 89 determined an 
increase in the amount of this cytokine, and a high peak level was detected after 
incubation of spleen cells with SK-OV-3. The release of IFN- by splenocytes 
from HURT-DNA vaccinated mice was comparable to that of mock group:  no 
production was observed after co-culture with syngeneic cells, while in the 
supernatants of spleen cells and SK-OV-3 co-culture a low production was 
detected. 
Overall, these data suggest that after HURT-DNA vaccination, unlike cell 
vaccination, the high humoral response was sufficient to prevent and delay tumor 
onset in HER-2 mice. 
 
2.3.3 Anti-HER-2 antibodies 
To further study the effectiveness of anti-HER-2 antibodies, we chose to 
focus on sera from HURT-DNA vaccinated mice because of the high humoral 
response in this group of animals and for the absence of xenogeneic stimuli that 
could affect the response. With this purpose, in vitro and in vivo experiments were 
performed to characterize anti-HER-2 antibodies.  
First, isotypes expressed in sera of HURT-DNA vaccinated animals were 
evaluated by indirect immunofluorescence (Figure 22A). MAMBO 89 and SK-
OV-3 were employed as substrate for anti-HER-2 antibodies. Among expressed 
isotypes, IgG1, IgG2a and IgG2b were well-represented and they were able to 
recognize both syngeneic and xenogeneic cell lines. 
HER-2 signaling activation was also evaluated (Figure 22B). MAMBO 89 
was incubated for 5 to 60 minutes with HURT-DNA sera and the expression of 
HER-2, AKT and the corresponding phosphorylated proteins was evaluated by 
Western Blot. An inhibitory effect mediated by antibodies was detected on 
analysed proteins. In detail, after 1 hour of treatment, anti-HER-2 antibodies, 
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compared with control mice sera, determined in cells a 57% decrease in the 
expression of activated p-HER-2 and a reduction was observed also on plasmatic 
HER-2 (38%). Focusing on the cytoplasmatic signaling effector AKT, in cells 
treated with antibodies the lowest expression was observed after 30 minutes of 
treatment (20%), while the most dramatic reduction in activated AKT was 
detected after 5 minutes of treatment with anti-HER-2 antibodies (36%). 
To assess the in vivo ability of anti-HER-2 antibodies to target and delay 
HER-2 carcinosis, the peritoneal metastatic model already described in section 
2.2.4 was employed. Immunodeficient mice were chosen to avoid any possible 
additive immunologic anti-tumor activity by the host, in order to evaluate the real 
contribution of anti-HER-2 antibodies alone. SK-OV-3 was injected in Rag2
-/-
;Il2rg
-/-
 mice and animals were treated for two weeks with pools of sera from 
mock- or HURT-DNA-vaccinated mice. After 5 weeks from challenge, total 
tumor weight in each mouse was evaluated (Figure 23). Mice treated with HURT-
DNA  group sera displayed a median tumor weight of 42 mg, much lower than 
that of animals treated with sera from mock-vaccinated mice (297 mg) 
(Wilcoxon’s non-parametric test, p=0.05). Hence, the passive immunization by 
anti-HER-2 antibodies produced by HURT-DNA vaccinated mice was effective in 
inhibiting HER-2-positive tumor growth in immunodeficient Rag2
-/-
;Il2rg
-/-
, 
despite the absence of most cellular and cytokine responses. 
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Table 1. HER-2 and 16 expression in cell lines derived from HER-2, 16 
and F1 tumors. MAMBO 89 derived from a HER-2 tumor; 143-VS, 302-IVD, 
156-VS and 156-IS derived from tumors arisen in F1 mice. All these cell lines 
were stabilized in vitro in the Laboratory of Immunology and Biology of 
Metastasis. MILAN 6 was obtained from a 16 tumor in the Laboratory of Dr. 
Serenella Pupa. The human HER-2-positive breast cancer cell line BT-474 was 
included in this analysis. Transcripts expression of HER-2 and 16 was calculated 
as Ct= CtHER-2/16-CtGAPDH. Abbreviations: MFI, Median Fluorescence Intensity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell line
MAMBO 89 0.7 17.4 1592
MILAN 6 19.7 1.4 301
143-VS 0.7 13.0 284
302-IVD -2.1 -2.7 1433
156-VS 11.6 -0.2 673
156-IS 11.4 0.8 392
BT-474 0.1 3.9 999
Ct HER2 Ct 16 Total HER2 (MFI)
Transcripts expression Protein expression
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Table 2. Spontaneous and induced metastatic spread in HER-2 mice. 
MAMBO 89 and MILAN 6 were injected intramammary (i.ma., spontaneous 
metastases) and intravenously (i.v., induced metastases) in HER-2 mice.  
 
 
  
Dose Incidence (%) Range
MAMBO 89 i.ma. 10
6
14 1/2 (50%) 2 0-4
MILAN 6 i.ma. 10
6
13 5/5 (100%) 6  1-16
MAMBO 89 i.v. 10
5
18 4/5 (80%) 2 0-4
MILAN 6 i.v. 10
5
13 5/5 (100%) 58 39-101
Cell line Route Median
Median 
week after 
cell injection
Lung metastases
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Table 3. Induced metastatic spread in FVB non-trasgenic mice. 
MAMBO 89 and MILAN 6 were injected intravenously (i.v) in 
immunocompetent non-tolerant syngeneic mice (FVB mice).  
 
 
 
  
Dose Incidence (%) Range
MAMBO 89 i.v. 10
6
13 8/8 (100%) 64 4-223
MILAN 6 i.v. 10
5
11 8/8 (100%) 211 104-257
Cell line Route
Median 
week after 
cell injection
Lung metastases
Median
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Table 4.  Treatment of induced HER-2 and 16 metastases with 
Trastuzumab and/or Dasatinib. MAMBO 89 (10
6
 cells) and MILAN 6 (10
5
 
cells) were injected i.v. in immunocompetent non-tolerant syngeneic mice (FVB 
mice). Mice were treated with Trastuzumab (4 mg/kg, i.p.) and/or with Dasatinib 
(50 mg/kg, per os). (A) Weight of the lungs minus the weight of metastases-free 
lungs. Median lung weight and range are shown. Statistical significances 
(Student’s t test): for MILAN 6, Control vs Trastuzumab/ Trastuzumab+Dasatinib 
p˂0.001. (B) Number of lung metastases. Incidence, median and range are shown. 
Statistical significances (Student’s t test): MAMBO 89, Control vs Trastuzumab/ 
Trastuzumab+Dasatinib p˂0.05; MILAN 6, Control vs Trastuzumab/ 
Trastuzumab+Dasatinib p˂0.001, Trastuzumab vs Trastuzumab+Dasatinib 
p˂0.01. 
 
A 
 
 
B 
  
Treatment
Control 62 ± 23 121 ± 15
Trastuzumab 50 ±   9 7 ±   7
Dasatinib 97 ± 33 138 ± 31
Trast+Das 63 ± 14 1 ±   8
MAMBO 89
Lung weight (mg)
MILAN 6
Treatment Incidence Median Range Incidence Range
Control 8/8 64 4-223 8/8 211 104-257
Trastuzumab 7/8 16 0-43 7/8 24 0-49
Dasatinib 7/8 90 0-169 8/8 172 65-256
Trast+Das 7/8 22 0-61 6/8 3 0-11
MAMBO 89 MILAN 6
Median
Figures and tables 
73 
 
 
 
Figure 1. Spontaneous mammary carcinogenesis in F1 model compared to 
HER-2 and 16 models. (A) Kaplan-Meier analysis. HER-2 mice n=40, 16 
mice n=24, F1 mice n=24. Incidence of mammary tumors in mice: HER-2 model 
35/40 (88%); 16 model 24/24 (100%); F1 model 24/24 (100%). Statistical 
significances (Mantel-Haenszel’s test): HER-2 vs 16 and HER-2 vs F1 p˂0.001. 
(B) Tumor multiplicity. Each point represents the mean number of tumors/mouse 
± standard error at death. HER-2 mice n=39, 16 mice n=24, F1 mice n=21. 
Statistical significances (Student’s t test): HER-2 vs 16 p˂0.01 at least from the 
5
th
 week; HER-2 vs F1 p˂0.01 at least from the 4th week; F1 vs 16 vs  p˂0.05 at 
least from the 22
nd
 week. (C) Kinetic of the growth of the first tumor. Each point 
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is the mean tumor volume ± standard error. HER-2 tumors n=23, 16 tumors 
n=30, F1 tumors n=23. Statistical significances (Student’s t test): HER-2 vs 16 
p˂ 0.05 at least; HER-2 vs F1 p˂ 0.05 at least between 1st and 5th weeks.  
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Figure 2. Autochthonous metastatic spread in HER-2, 16 and F1 models.  
Each point represents the number of autochthonous lung metastases in a mouse. 
HER-2 mice n=26, 16 mice n=9, F1 mice n=16. Incidence of lung metastases in 
mice: HER-2 model 14/26 (54%); 16 model 5/9 (56%); F1 model 8/16 (50%). 
Median number of lung metastases: HER-2 model median=1; 16 model 
median=1; F1 model median=0.5. No statistical significances were found among 
the models. 
 
  
HER-2 16 F1
0
10
20
30
40 54%          56%           50%
L
u
n
g
 l
e
si
o
n
s
Figures and tables 
76 
 
 
Figure 3. HER-2 expression in tumors. (A) Expression of total HER-2 protein 
on cell membrane by Cytofluorimetry. Each point represents a tumor. HER-2 
tumors n=43, 16 tumors n=26, F1 tumors n=59. Median expression of HER-2 
protein: HER-2 model median=698; 16 model median=233; F1 model 
median=221. Statistical significances (Student’s t test): HER-2 vs 16 and HER-2 
vs F1 p˂0.0001. (B) Expression of HER-2 and 16 transcripts. Each point 
represents a tumor. HER-2 tumors n=10, 16 tumors n=8, F1 tumors n=41. 
GAPDH was employed as house-keeping gene. Transcrips expression was 
calculated as follows: CtHER-2/16= CtHER-2/16- CtGAPDH.  
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Figure 4. Sensitivity to Trastuzumab.  
(A) In vitro (3-D culture) sensitivity to Trastuzumab (10 g/ml). Cell lines 
derived from HER-2, 16 and F1 mammary tumors. Each bar represents the mean 
± standard error percentage of colonies grown in 2-4 independent experiments. 
BT-474, MILAN 6, 156-VS and 156-IS were sensitive to Trastuzumab. (B,C) In 
vivo sensitivity to Trastuzumab in immunocompetent non-tolerant syngeneic mice 
(FVB mice) implanted with a F1-derived mammary tumor. Trastuzumab (4 
mg/Kg) was administered i.p. twice a week for four weeks. (B) Kaplan-Meier 
analysis. Incidence of mammary tumor in mice: untreated mice 4/5 (80%); treated 
mice 0/5 (0%). (C) Kinetic of the growth of  F1 tumor. Each point represents the 
mean tumor volume ± standard error. Statistical significances (Fisher’s exact test): 
p˂ 0.05.  
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Figure 5. Sensitivity to Lapatinib (alone or in combination with 
Trastuzumab).  
(A) In vitro (3-D culture) sensitivity to Lapatinib (1 M). Each bar represents the 
mean ± standard error percentage of colonies grown in 2-6 independent 
experiments. Statistical significances (Student’s t test): for Lapatinib MAMBO 
89/143-VS vs BT-474/MILAN 6/ 302-IVD/156-VS/156-IS p˂0.05 (B) In vitro 
sensitivity to Lapatinib and/or Trastuzumab. Each bar represents the mean ± 
standard error in 1-3 independent experiments. Statistical significances when n˃1 
(Student’s t test): for Lapatinib + Trastuzumab MAMBO 89 vs 302-IVD p=0.054; 
143-VS vs 302-IVD p˂0.005. 
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Figure 6. Sensitivity to Dasatinib (alone or in combination with Trastuzumab 
and/or Lapatinib).  
(A) In vitro (3-D culture) sensitivity to Dasatinib (1 M) alone or in combination 
with Trastuzumab (10 g/ml) and/or Lapatinib (1 M). Each bar represents the 
mean ± standard error of 4-6 counts of the same experiment. Statistical 
significances among cell lines (Student’s t test): for Dasatinib MAMBO 89 vs 
MILAN 6/143-VS/302-IVD p˂0.001, 302-IVD vs MILAN 6/143-VS p˂0.001; for 
Dasatinib+Lapatinib MAMBO 89 vs MILAN 6/143-VS p˂0.01; for  
Dasatinib+Trastuzumab MAMBO 89 vs MILAN 6/143-VS/302-IVD p˂0.001; for 
Dasatinib+Lapatinib+Trastuzumab MAMBO 89 vs MILAN p˂0.01, MAMBO 89 
vs 143-VS/302.IVD p˂0.05. Statistical significances among treatments (Student’s 
t test): for MAMBO 89 Dasatinib vs Dasatinib+Lapatinib/ 
Dasatinib+Lapatinib+Trastuzumab p˂0.001; for 302-IVD Dasatinib vs 
Dasatinib+Lapatinib p˂0.05, Dasatinib vs Dasatinib+Trastuzumab p˂0.005, 
Dasatinib vs Dasatinib+Lapatinib+Trastuzumab p˂0.001. 
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Figure 7. Sensitivity to NVP-BKM120.  
In vitro (3-D culture) sensitivity to NVP-BKM120 (1 M and 0.1 M). Each bar 
represents the mean ± standard error percentage of colonies grown in 1-2 
independent experiments. Statistical significances (Student’s t test) when n˃1: for 
BKM120 0.1 M 302-IVD vs 156-VS/156-IS p˂0.05.  
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Figure 8. Cytofluorimetric expression of Enhanced Green Fluorescent Protein 
(EGFP) and HER-2 in MDA-MB-453-EGFP. 
 (A) In green EGFP expression in MDA-MB-453 transduced with EGFP (MDA-
MB-453-EGFP) is shown. (B) In red HER-2 expression in MDA-MB-453-EGFP. 
Empty profile shows basal fluorescence of MDA-MB-453-EGFP after incubation 
only with the secondary antibody.  X axis reports fluorescent intensity in arbitrary 
units, y axis reports the number of events.  
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Figure 9. Treatment of spontaneous and induced HER-2 positive human 
metastases with NVP-BKM120. 
(A) Incidence of spontaneous metastases in different sites after intramammary 
injection of MDA-MB-453-EGFP (10
7
 cells) in Rag2
-/-
;Il2rg
-/-
 mice. Mice were 
treated with NVP-BKM120 (50 mg/kg, per os) starting seven days after cell 
injection. Vehicle n=6, NVP-BKM120 n=5. (B) Incidence of induced metastases 
in different sites after intravenous injection of MDA-MB-453-EGFP (2x10
6
 cells). 
Mice were treated with NVP-BKM120 (50 mg/kg, per os) starting one day after 
cell injection. Vehicle n=9, NVP-BKM120 n=6. Statistical significances (Fisher’s 
exact test): Vehicle vs NVP-BKM120 in brain, bone marrow and liver p˂0.05 at 
least.  
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Figure 10. Inhibition of HER-2-positive metastatic growth by NVP-BKM120 
in brain and lungs.  
Representative pictures of dissected control and treated mouse brains (ventral 
view) and lungs. Lightools imaging system was used to detect fluorescent 
metastatic deposits.  
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Figure 11. Quantification of HER-2-positive induced metastases after 
treatment with NVP-BKM120.  
The mean metastatic burden ± standard error was evaluated in mice treated i.v. 
with MDA-MB-453-EGFP. Untreated mice n=9, NVP-BKM120 n=6. Percentage 
inhibition is shown in each graph above NVP-BKM120 bar. (A) Quantitative 
analysis of brain metastases in Real-time PCR calculated as number of human 
cells in mouse brain. (B,C) Cytofluorimetric quantification of HER-2-positive 
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cells in brain (B) and femoral bone marrow (C). (D,E,F) Visual count of 
metastatic sites per mouse. Statistical significances (Student’s t test): panel A, B, 
D and F untreated vs NVP-BKM120 p˂0.05.  
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Figure 12. MEK inhibition by siRNA in MCF-10A and BT-474. 
MCF-10A and BT-474 were transfected with siRNA Control, siRNA MEK1, 
siRNA MEK2 and siRNA MEK1 + siRNA MEK2 (Dharmacon) at a final 
concentration of 50 nM. An EGF time course was included. Tubulin was 
employed as house-keeping protein. (A) Western blots on MCF-10A lysates; (B) 
Western blots on BT-474 lysates. 
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Figure 13. MEK inhibition by treatment with UO126 of MCF-10A and BT-
474. 
MCF-10A and BT-474 were treated for 1 hour with UO126 5 M. Western blots 
were  performed on cell lysates. An EGF time course was included. Tubulin was 
employed as house-keeping protein.    
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Figure 14. In vitro sensitivity to R-LM249 and Trastuzumab.  
(A) Cytotoxicity of R-LM249 (10 pfu/cell) in three HER-2-positive cancer cell 
lines (BT-474 and MDA-MB-453, breast cancer; SK-OV-3, ovarian cancer). 
HER-2-low/negative breast cancer cell line MDA-MB-231 was included as 
negative control. Cell viability was measured by alarmBlue assay. Each point 
represents the mean of quadruplicates + standard deviation expressed as 
percentage with respect to uninfected cells. (B) Sensitivity to Trastuzumab after 
72 hours culture. Mean ± standard error from 3-5 independent experiments is 
shown. Abbreviations: pfu, plaque-forming units. 
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Figure 15. Therapy of localized HER-2-positive human breast cancer with R-
LM249.  
(A,B) Tumor growth inhibition by R-LM249. BT-474 and MDA-MB-453 (10
7
 
cells) were injected s.c. in Rag2
-/-
;Il2rg
-/-
 mice. R-LM249 (2x10
7
 or 10
8
 pfu) was 
administered intratumorally at the indicated days (red arrows below x axis). Each 
point represents the mean tumor volume ± standard error until all mice per group 
are alive (in each group n=5). Statistical significances (Student’s t test): for BT-
474, Vehicle vs R-LM249 2x10
7
 p˂0.05 at least from 20th day, Vehicle vs R-
LM249 10
8
 p˂0.05 at least from 13th day; for MDA-MB-453, Vehicle vs R-
LM249 2x10
7
/10
8
 p˂0.05 at least from 13th day. (C,D) Kaplan-Meier analyses. A 
vertical dashed line shows the end of treatment with R-LM249 (67 days). (C) 
Median survival days: Vehicle=73, R-LM249 2x10
7
=139, R-LM249 10
8
=146. (D) 
Median survival days: Vehicle=98, R-LM249 2x10
7
=125, R-LM249 10
8
=132. 
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Statistical significances (Mantel-Haenszel’s test): for BT-474 and MDA-MB-453, 
Vehicle vs R-LM249 2x10
7
/10
8
 p˂0.01 at least.  
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Figure 16. Therapy of metastatic HER-2-positive human breast cancer with 
R-LM249. MDA-MB-453 (2x10
6
 cells) were injected i.v. in Rag2
-/-
;Il2rg
-/-
 mice. 
R-LM249 (10
8
 pfu) was administered i.p. in 4 weekly injections. Vehicle n=9, R-
LM249 n=10. (A, C, E) Incidence of macroscopic metastases in organs at 
necropsy. (B, D, F) Quantification of metastatic burden in organs by Real-time 
PCR. Each bar represents the mean ± standard error in each group. Statistical 
significances: (A), p˂0.0001 (Fisher’s exact test); (B), p=0.0004 (Student’s t test 
and non-parametric Wilcoxon’s rank sum test); (C), p=0.07 (Fisher’s exact test); 
(D), p=0.056 (Student’s t test), p=0.03 (non-parametric Wilcoxon’s rank sum 
test). 
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Figure 17. Therapy with R-LM249 of peritoneal carcinosis of HER-2-positive 
ovarian carcinoma in nude mice.  
Kaplan-Meier analysis. SK-OV-3 (2x10
6
 cells) were injected i.p. in nude mice. R-
LM249 (2x10
7
 pfu) was administered  i.p. weekly at the indicated days (red 
arrows below x axis), starting 3 days after cell injection. In each group n=5. 
Median survival days: Vehicle=103, R-LM249=440. Statistical significances 
(Mantel-Haenszel’s test): p=0.02. 
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Figure 18. Therapy with R-LM249 of peritoneal metastatic HER-2-positive 
ovarian cancer in Rag2
-/-
;Il2rg
-/-
 mice. 
SK-OV-3 (2x10
6
 cells) were injected i.p. in Rag2
-/-
;Il2rg
-/-
 mice. R-LM249 (10
8
 
pfu) was administered i.p. weekly for 5 weeks, starting 3 days after cell injection. 
Vehicle n=5, R-LM249 n=7. (A) Incidence of peritoneal carcinosis (B) Mean 
cumulative weight of peritoneal metastates ± standard error. Statistical 
significances (Student’s t test): p=0.007. (C) Incidence of peritoneal ascites. 
Statistical significances (Fisher’s exact test): p=0.027. 
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Figure 19. R-LM249 efficacy in targeting and inhibiting HER-2-positive 
ovarian cancer metastases. 
Representative pictures of Rag2
-/-
;Il2rg
-/-
 mice after the i.p. injection of SK-OV-3 
and i.p. treatment with R-LM249. (A) Control mouse (treated with PBS). Green 
arrows show multiple peritoneal metastases. (B) Metastases-free mouse treated 
with R-LM249.  (C) Distribution of R-LM249 transfected with EGFP in a mouse 
with multiple peritoneal metastases. Yellow-brown fluorescence: 
autofluorescence of mouse fur and visceral organs. 
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Figure 20. Immunopreventive efficacy of anti-HER-2 vaccines on HER-2 
model.  
Mock group (untreated, vehicle and pVAX1) n=31, HER-2-Cell vaccine n=8, 
HURT-DNA vaccine n=12. (A) Kaplan-Meier analysis. Incidence of mammary 
tumors in HER-2 mice: Mock  87%; HER-2-Cell vaccine 79%; HURT-DNA 
vaccine 36%. Statistical significances (Mantel-Haenszel’s test): Mock vs HER-2-
Cell/HURT-DNA vaccines p˂0.05. (B) Tumor multiplicity. Each point represents 
the mean number of tumors/mouse ± standard error at death. Statistical 
significances (Student’s t test): Mock vs HER-2-Cell vaccine p˂0.05 at least from 
50
th
 week; Mock vs HURT-DNA p˂0.05 at least from 54th week.   
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Figure 21. Humoral and cell-mediated immune responses to anti-HER-2 
vaccines in HER-2 model. 
(A) Serum anti-HER-2 antibodies after vaccination with HER-2-Cell or HURT-
DNA vaccines. Median value of each group is shown as a horizontal bar. Mock 
n=2-5, HER-2-Cell n=5-10, HURT-DNA n=5-11. Statistical significances 
(Wilcoxon’s non-parametric test): HURT-DNA vs HER-2-Cell p˂0.05 at least at 
4
th
, 24
th
 and 40
th
 weeks of treatment. (B) Interferon  (IFN-) production by spleen 
cells after vaccination. Mock n=6, HER-2-Cell n=4, HURT-DNA n=3. Each bar 
represents the mean ± standard error of each group. Spleen cells were cultured 
alone (spont) or in the presence of HER-2-positive syngeneic (syn-HER-2, 
MAMBO 89) or xenogeneic (xeno-HER-2, SK-OV-3) cancer. Statistical 
significances: for syn-HER-2 and xeno-HER-2, HER-2-Cell vs Mock/HURT-
DNA p˂0.05. 
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Figure 22. Anti-HER-2 antibodies produced by HER-2 mice vaccinated with 
HURT-DNA. 
(A) Isotypes expression of anti-HER-2 antibodies by indirect immunofluorescence 
after incubation of sera with HER-2-positive syngeneic (syn-HER-2, MAMBO 
89) or xenogeneic (xeno-HER-2, SK-OV-3) cancer cells. (B) Activation of HER-2 
signaling in syngeneic HER-2 positive cell line (MAMBO 89) after treatment 
with anti-HER-2 antibodies. Time of exposure to antibodies is shown. Band 
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intensity was detected by densitometric analysis and normalized over actin. The 
percentage decrease between M and H is shown. Abbreviations: U, untreated 
cells; M, cells treated with sera from Mock-vaccinated mice; H, cells treated with 
sera from mice vaccinated with HURT-DNA. 
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Figure 23. Tumor growth inhibition by anti-HER-2 antibodies.  
HER-2-positive cell line SK-OV-3 (2x10
6
) was injected i.p. in Rag2
-/-
;Il2rg
-/-
 
mice. Mice were treated i.p. with sera from Mock mice (untreated or pVAX1-
treated) or from mice vaccinated with HURT-DNA at day 1, 3, 7 and 14. Each 
point represents the weight of all tumors grown intraperitoneally in each mouse. 
Mock n=8, HURT-DNA n=6. Median tumor weight is shown as horizontal bar. 
Statistical significances (Wilcoxon’s non-parametric test): p=0.05. 
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The project described in this thesis had two aims: the study of the 
contribute of wild-type full-length HER-2 and of its splice variant 16 to 
mammary HER-2-positive carcinogenesis and the evaluation of innovative anti-
HER-2 strategies against HER-2-positive breast cancer. 
Besides the 185kDa protein, over the years other isoforms of HER-2 were 
found in HER-2-positive breast cancers, including C- and N-terminal fragments of 
the protein (p95HER-2 and H2NTF) and the splice variant 16 (Kwong and 
Hung, 1998; Arribas et al., 2011; Morancho et al., 2013). In 16 isoform, the in-
frame deletion of exon 16 (48 bp) determines the lack of 16 aminoacids, including 
two cysteines,  in the juxtamembrane region (Kwong and Hung, 1998). Due to the 
loss of these cysteine residues, intermolecular disulfide bonds with other 
monomers are promoted, triggering a stronger signal transduction in respect to 
HER-2 (Castiglioni et al., 2006).  
The transforming ability of wild-type HER-2 has been widely investigated 
since the discovery of its connection to cancer in 1984 by Schechter and 
colleagues (Schechter et al., 1984) and led to the development of revolutionary 
anti-HER-2 agents. Due to their relatively recent detection, more studies on HER-
2 isoforms are required to shed light into their role in HER-2 carcinogenesis and 
in the development of resistance to current anti-HER-2 agents.  
With this purpose, in this thesis the comparative study of mammary 
carcinogenesis in three mouse models transgenic for different forms of HER-2 is 
reported: two mouse strains that carry HER-2 proto-oncogene (HER-2 model; 
Finkle et al., 2004) or 16 variant gene (16 model; Marchini et al., 2011) 
respectively, and a hybrid model transgenic for both genes (F1 model). 
 Confirming the findings of Marchini and co-workers (Marchini et al., 
2011), the presence of 16 caused the anticipation of tumor onset in mice. 
Furthermore, mammary carcinogenesis was observed in all 16-expressing mice, 
while 12% of HER-2 mice were still tumor free at 100 weeks of age. The 
simultaneous expression of 16 and HER-2 did not determine any difference in 
F1 tumor latency compared to that of 16 mice, suggesting a dominant role of the 
splice variant in F1 phenotype.  
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The evaluation of tumor multiplicity, i.e. the number of tumors per mouse, 
showed once again the aggressiveness of 16 isoform in respect to HER-2. 
Models carrying 16 shared a dramatic increase in tumor multiplicity in respect to 
HER-2 mice, even though a significant higher number of tumors per mouse was 
observed in F1 mice if compared to 16 mice starting from the 22nd week of age.  
In light of these findings, 16 isoform appears to be a more aggressive 
oncogene in respect to wild-type HER-2, in which additional genetic events, 
besides amplification, are required to trigger mammary carcinogenesis. 
Supporting these conclusions, Marchini and colleagues proposed the candidacy of 
16 as the transforming form of HER-2, showing that its specific expression by 
mammary tumor cells was sufficient to induce tumor onset in 16 mice. Notably, 
the splice variant was not expressed in non-neoplastic mammary glands or other 
tissues (Marchini et al., 2011). On the contrary, in HER-2 model developed by 
Finkle and co-workers wild-type HER-2 was detected in mammary tumors as well 
as in normal mammary glands and several other tissues. Furthermore, analyzing 
mammary tumors arisen in HER-2 mice, the group led by Finkle found sequence 
anomalies, e.g. deletions, in the same region that is deleted in 16 isoform, 
suggesting the need for a “second hit” in mice transgenic for wild-type HER-2 to 
trigger carcinogenesis (Finkle et al., 2004). Previously, studies on the rat 
homologue of HER-2 (Neu) and on its mutated (i.e. activated) isoform NeuT 
highlighted the necessity of additional mutations, beside Neu amplification, to 
foster mammary carcinogenesis. The delayed tumor onset in Neu mice in respect 
to NeuT mice was attributed to the acquisition of genetic abnormalities. In 
particular, somatic mutations, including deletions, were found in tumors arisen in 
Neu mice (Guy et al., 1992; Siegel et al., 1994) in the same region of exon 16 
deletion and of HER-2 genetic mutations observed in HER-2 mice (Finkle et al., 
2004). Discordant findings have been achieved so far in humans, where HER-2-
amplified breast cancers do not display genetic mutations as those observed in 
preclinical models (Moasser, 2007; Arteaga and Engelman, 2014).  
Despite the enhanced transforming ability of 16, tumors in 16 and F1 
mice grew slower than those of HER-2-expressing mice. Furthermore, no 
differences in autochthonous metastatic spread were found among the three 
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models. Thus, the expression of the splice variant seems significant for early 
carcinogenic events, but it may not be so relevant for later stages as progression 
and metastasis development.  
However, transgenic mice are, in general, inappropriate for the study of 
late stages of breast cancer, i.e. the metastatic spread, because of the low 
incidence of metastases (Ottewell et al., 2006; Saxena and Christofori, 2013). To 
overcome this issue, as well as to better define the role of HER-2 and 16 in 
advanced disease, syngeneic transplantation models were employed in this 
project. The injection of MAMBO 89 (derived from a tumor of a HER-2 mouse) 
or MILAN 6 (obtained from a tumor arisen in a 16 transgenic mouse) allowed to 
compare HER-2- and 16-driven metastasis formation in HER-2-tolerant or non-
tolerant mice. Both strains were permissive to the metastatic growth of cell lines 
in the lungs, but MILAN 6 transplantation models were more prone to the 
development of lung metastases. Using a xenotransplantation model, Alajati and 
colleagues previously showed the metastatic ability of 16, although they did not 
compare it with that of HER-2 (as done in this thesis) (Alajati et al., 2014). 
Scientists observed a high incidence of induced and spontaneous lung metastases 
in immunodeficient mice (SCID/Beige) that had previously received the i.v. or 
i.ma. injection of the human cell line MCF-10A transfected with 16. However, 
compared with the findings of this thesis, metastases were not found in all 
animals, likely because of the choice of the transplantation model. Indeed, the 
immunodeficient mouse strain that they employed is characterized by reduction, 
but not complete absence, of NK cells and phagocytes activity that could prevent 
the growth of human cells (Thomsen et al., 2008). Furthermore, MCF-10A is an 
immortalized cell line (i.e. not prone to terminal differentiation or senescence), 
but with a non-neoplastic origin (it derives from epithelial breast tissue of a 
woman with fibrocystic disease).  
The expression of total plasmatic HER-2 protein was assessed in F1 
tumors and compared to that of HER-2- and 16-driven tumors. The differential 
evaluation of wild-type HER-2 and 16 protein levels on tumor cells surface was 
hampered by the lack of antibodies that specifically target each isoform. Models 
carrying 16 gene showed  similar HER-2 levels in tumors, significantly lower 
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than those displayed by HER-2 transgenic mice. Three main reasons can be 
mentioned to clarify these observations. First, the model transgenic for wild-type 
HER-2 alone could have a real higher expression of the cell membrane receptor. 
Secondly, an impaired Ig binding to 16 protein might cause its lower detection 
on tumor cells. Finally, these findings could be attributed to the different number 
of transgene copies inserted in HER-2 (30-50 copies) and 16 (5 copies) models 
(Finkle et al., 2004; Marchini et al., 2011).  
The coexistence of HER-2 and 16 in mammary tumors arisen in the 
hybrid model was shown by the presence of the transcripts of both isoforms. In 
humans, HER-2 and 16 transcripts coexist in nearly half HER-2-positive breast 
cancers and in 90% of patients with locally advanced disease, i.e. with invasive 
cancer cells in the lymph nodes (Castiglioni et al., 2006; Mitra et al., 2009). Thus, 
if compared with HER-2 and 16 models, F1 mice represent a further step in the 
attempt to mimic the human situation in preclinical models. According to the 
expression of HER-2 and 16, F1 mammary tumors were classified in three 
groups: the majority displayed expression levels comparable to 16 tumors (low 
HER-2, high 16), while just a couple of tumors were similar to HER-2 tumors 
(high HER-2, low 16). Finally, 12% of tumors coexpressed HER-2 and 16 at 
high/intermediate levels (high HER-2, high/intermediate 16). In general, the 
heterogeneity found in F1 tumors reflects what happens in human breast cancers, 
whose HER-2 expression in different patients, as well as in different portions of a 
single tumor, show peculiar characteristics (Arteaga and Engelman, 2014).  
Hence, the heterogeneous expression of HER-2 and 16 enhances the 
preclinical value of F1 model, that appears even more suitable for investigational 
studies on new therapeutic strategies against HER-2. With this purpose, four cell 
lines were obtained from F1 tumors with different expression levels of HER-2 and 
16 transcripts and in vitro stabilized: 143-VS (high HER-2, low 16), 156-VS 
and 156-IS (low HER-2, high 16), 302-IVD (high HER-2, high 16). As 
described below, in this project the susceptibility of these cell lines to anti-HER-2 
drugs was tested in a 3-D culture, but they will be employed in future therapeutic 
studies on HER-2-positive syngeneic models. 
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Since  the development of Trastuzumab, a new era for the treatment of 
HER-2-positive breast cancer began. However, despite an initial drug response, 
many patients finally become resistant to anti-HER-2 agents that have been 
already approved by FDA (Arteaga and Engelman, 2014). Early studies on 16 
splice variant reported that Trastuzumab is ineffective when applied to 16-
expressing cells in vitro (Castiglioni et al., 2006; Mitra et al., 2009). In contrast, 
in the current study a high susceptibility to the humanized monoclonal antibody 
was shown in all cell lines with a high expression of 16 (156-IS, 156-VS and 
MILAN 6), while cell lines expressing HER-2 at high levels (MAMBO 89, 143-
VS and 302-IVD) were resistant to the drug. The effectiveness of Trastuzumab on 
high-16 tumor cells was confirmed in vivo by the inhibition of F1 tumor growth 
in a syngeneic model. Supporting these findings, Alajati and co-workers 
previously showed that Trastuzumab was able to block the growth of MCF-10A 
transfected with 16 and injected orthotopically in SCID/Beige mice (Alajati et 
al., 2013). Notably, the lower administration dose of Trastuzumab in the 
syngeneic model (4 mg/kg instead of 10 mg/kg delivered to xenotransplanted 
animals) was balanced by  the compromised immune system of SCID/Beige mice, 
that were therefore unlikely to trigger ADCC after Trastuzumab treatment because 
of the absence of the most active ADCC effectors.  
The resistant phenotype shown in vitro by F1 cell lines expressing HER-2 
at a high level and, above all, by MAMBO 89 could be attributed to the presence 
of additional HER-2 transforming mutations on HER-2 gene in the original 
tumors (Finkle et al., 2004). In contrast with these in vitro findings, treatment 
with Trastuzumab was able to significantly reduce the development of both HER-
2 and 16 induced metastases in a syngeneic model. However, the reduction in 
the HER-2 metastatic burden was observed  in a lower extent if compared with 
that of treated 16 mice. The efficacy of monoclonal antibodies in overcoming in 
vitro resistance of MAMBO 89 may be due to the triggering of Trastuzumab-
mediated ADCC.  
Overall, the presence of 16 correlated with a better response to 
Trastuzumab. Supporting the role of HER-2 isoforms in Trastuzumab-positive 
response, two recent studies reversed the notion that CTF cause resistance to the 
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drug. In fact, despite the intrinsic resistant phenotype of p95HER-2 because of the 
lack of Trastuzumab binding site (Arribas et al., 2011), the studies conducted by 
Parra-Palau and Scaltriti associated the expression of CTF in human samples of 
HER-2-positive breast cancer to high levels of HER-2 and, unexpectedly, to 
sensitivity to Trastuzumab (Parra-Palau et al., 2014; Scaltriti et al., 2014). In 
particular, Parra-Palau and colleagues suggested that the accumulation of HER-2 
at the cell surface was caused by p95HER-2-driven inhibition of phospho-HER-2 
and stabilization of HER-2 (Parra-Palau et al., 2014). Indeed, the study conducted 
by Gosh and colleagues previously demonstrated that high levels of HER-2 
homodimers, which correlated with HER-2 expression, were related to increased 
Trastuzumab activity (Ghosh et al., 2011). In light of these findings, the enhanced 
susceptibility to Trastuzumab here displayed by 16-expressing tumor cells could 
be explained by the demonstrated formation of stable and constitutive active 16 
homodimers (Castiglioni et al., 2006). Conversely, in vitro resistance and lower in 
vivo sensitivity to Trastuzumab of cell lines with high HER-2 might be caused, 
besides genetic mutations of HER-2, by the presence of less stable HER-2 
homodimers and/or by a larger amount of HER-2-containing heterodimers.  
 All HER-2, 16 and F1 cell lines were susceptible in vitro to the 
treatment with another anti-HER-2 agent, the tyrosine kinase inhibitor Lapatinib. 
However, the drug was more effective on 16-expressing cells, where a  complete 
inhibition of cell growth was observed. This evidence could be explained, 
similarly to Trastuzumab sensitivity,  by the high dependence of cell signaling on 
stable 16 homodimers, whose constitutive catalytic activity may be highly 
hampered by the drug. No additional effect was observed in vitro after combining 
Lapatinib with Trastuzumab in HER-2-expressing cell lines (MAMBO 89 and 
143-VS). In the other cell lines the statistical evaluation of the combinatorial-
regimen efficacy could not be investigated because of their complete growth 
inhibition after treatment with Lapatinib alone and/or because no replicates of the 
experiments were performed. However, Scaltriti and colleagues (Scaltriti et al., 
2014), showed that the benefit for the combination of Lapatinib with Trastuzumab 
could be predicted by total levels of HER-2 that, as suggested by Gosh and co-
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workers, correlate with high levels of HER-2 homodimers (Ghosh et al., 2011), 
including 16 homodimers.   
A wide signaling network is triggered by HER-2 and the other ErbB 
members after dimers formation. In particular, MAPK and PI3K-AKT are the 
most activated cascades downstream to HER-2 (Yarden and Sliwkowski, 2001; 
Arteaga and Engelman, 2014). In addition, Src kinase activation has been 
correlated to HER-2- and 16-dependent signal transduction. In particular, 
phospho-Src was connected to HER-2/HER-3 interaction and it was suggested as 
convergent point of multiple upstream signals, thus conferring resistance to anti-
HER-2 agents (Tan et al., 2005; Zhang et al., 2011; Rexer et al., 2011). 
Furthermore, Src activation was specifically related to 16-driven signal 
trasduction (Mitra et al., 2009; Marchini et al., 2011; Castagnoli et al., 2014). 
Thus, besides HER-2 receptor, these intracellular effectors represent valuable 
targets for new anti-HER-2 strategies (Arteaga and Engelman, 2014).  
Indeed, in this thesis the activity of three intracellular inhibitors was 
investigated: the Src inhibitor Dasatinib, the PI3K inhibitor NVP-BKM120 and 
MEK dual inhibitor UO126. Susceptibility to Dasatinib was evaluated both in 
vitro and in vivo. In 3-D culture the drug was effective on all cell lines derived 
from HER-2, 16 and F1 models. Nevertheless, the presence, even at very low 
levels, of 16 determined a much more evident therapeutic effect, thus supporting 
the 16/Src correlation suggested in previous studies (Mitra et al., 2009; Marchini 
et al., 2011; Castagnoli et al., 2014). In vivo, when combined with Trastuzumab, 
Dasatinib was able to inhibit the growth of 16 metastases in a higher extent in 
respect to Trastuzumab alone, suggesting the potential efficacy of Src inhibitor 
also in a preclinical setting, besides in in vitro experiments. Combining Dasatinib 
with HER-2 targeted agents showed additional effect also in vitro, thus supporting 
the notion that combinatorial regimens targeting different “layers” of HER-2 
signaling may be more effective than single-agent treatments (Yarden and Pines, 
2012; Arteaga and Engelman, 2014). For example, Trastuzumab resistance 
displayed by MAMBO 89 was overcome by the independent administration of 
both Dasatinib and Lapatinib, but their combination caused a more potent 
inhibition of tumor cell growth.  
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The rationale of targeting PI3K with NVP-BKM120 was the hyper-
activation of PI3K-AKT pathway in HER-2-positive breast tumors, connected to 
the formation of the highly active HER-2/HER-3 heterodimer (Lee-Hoeflich et 
al., 2008; Chakrabarty et al., 2013). All HER-2, 16 and F1 cell lines were 
strongly inhibited by the drug at the higher concentration chosen for in vitro 
experiments (1 µM), highlighting the importance of targeting effectors belonging 
to PI3K-AKT signaling cascade. 
However, targeting only a signaling pathway is thought to be a frequent 
cause for acquired resistance to single-agent treatment, because of the feedback 
activation of other cascades (Arteaga and Engelman, 2014). In this thesis, 
MEK1/MEK2 inhibition in MCF-10A and BT-474 by siRNA or UO126 
determined an increase in HER-2 activation, confirming the findings of earlier 
studies. In particular, Turke and colleagues demonstrated that the treatment of 
BT-474 with a MEK inhibitor (AZD6244) was able to activate ErbB receptors 
(including HER-2) by releasing a negative feedback on ErbB dimerization. As a 
consequence, the impaired MAPK cascade was compensated by the strong 
activation of PI3K-AKT pathway (Turke et al., 2012). Similarly, two studies 
showed that the inhibition of PI3K-AKT cascade in the same cell line caused the 
potent activation of HER receptors and of MAPK pathway (Chandarlapaty et al., 
2011; Serra et al., 2011).  
The importance of HER-2/MAPK pathway correlation was underlined also 
in a therapeutic setting. Gayle and co-workers observed a sustained MAPK 
activation in HER-2-positive cancer cell lines resistant to Lapatinib. Therefore, 
combining the drug with MEK suppression (by drugs-mediated inhibition as well 
as by dual silencing of MEK1/MEK2) they succeeded in blocking the growth of 
resistant cancer cells (Gayle et al., 2013). Almost symmetrically, Chandarlapaty 
and colleagues showed that the combinatorial regimen of a AKT inhibitor and 
Lapatinib determined the reduction of ErbB receptors activation (Chandarlapaty et 
al., 2011).  
Besides the increase in phosho-HER-2, cells treated with UO126 displayed 
high levels of phospho-MEK1/2. Notably, no increase of constitutive MEK 1 and 
MEK 2 was observed. UO126 inhibition of MEK1/MEK2 is non-competitive with 
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respect to ATP (Duncia et al., 1998), allowing MEK activation but blocking 
MEK-mediated ERK activation. Consequently, phospho-MEK1/2 accumulation 
could be attributed to its inability to phosphorylate the downstream effector ERK. 
Otherwise, lower levels of phospho-ERK could relieve a negative feedback on 
upstream signaling effectors of the pathway (e.g. Raf or Ras) or directly on ErbB 
receptors. In light of this explanation, the accumulation of activated MEK1/2 
could be the direct consequence of the increase in phospho-HER-2. The 
knockdown of MEK 1 and MEK2 by siRNA did not allow to detect this increase, 
likely because of the low/absent expression of constitutive MEK isoforms. 
 Importantly, BT-474 is known to coexpress HER-2 and 16. In in vitro 
therapeutical experiments its sensitivity to anti-HER-2 agents was comparable to 
that of F1 cell lines. Hence, cells derived from the hybrid model can successfully 
predict the response of human HER-2-positive cancer cells to treatments. In 
addition, in the attempt to find correlations between drug-resistant feedback 
cascades and heterogeneous levels of HER-2 and 16, F1 cell lines could be 
employed besides BT-474.  
Xenotransplantation models have been widely used for the study of HER-
2-positive breast cancer and for the development of new anti-tumor and anti-
metastatic approaches targeting HER-2. In the Laboratory of Immunology and 
Biology of Metastasis a multiorgan metastatic model of HER-2-positive breast 
cancer was developed. It consists of the i.ma. or  i.v. injection of human HER-2-
positive breast cancer cell lines in immunodeficient Rag2
-/-
;Il2rg
-/-
 mice, that lack 
mature T, B and NK cells. The metastatic pattern in Rag2
-/-
;Il2rg
-/-
 mice well 
reproduces the multiorgan metastatic situation displayed by advanced HER-2-
positive breast cancer patients. In particular, the high incidence of brain 
metastases makes this model the perfect target for new therapeutic approaches. In 
this thesis, Rag2
-/-
;Il2rg
-/-
 mice were employed to study the efficacy of NVP-
BKM120 in inhibiting metastases to brain and other organs and of an oncolytic 
virus retargeted against HER-2 (Nanni et al., 2012; Nanni et al., 2013).  
NVP-BKM120 was effective in reducing the incidence of metastatic 
spread in many organs, especially brain, femoral bone marrow and liver. Using a 
specific quantitative analysis, a more than 90% reduction in the brain metastatic 
Discussion 
112 
 
burden was detected after treatment with the drug, underlining its ability to cross 
the blood-brain barrier and stop the growth of HER-2-positive tumor cells. In 
addition, NVP-BKM120 was able to efficiently inhibit metastases to the bones 
and, in general, to all sites (Nanni et al., 2012). Notably, the model here described 
was obtained by the injection of MDA-MB-453, that is a Trastuzumab-resistant 
cell line. Hence, its current usefulness is undeniable. 
The high clinical impact of brain metastases in HER-2-positive breast 
cancer patients (Singh et al., 2014) enhances the potential role of some small 
molecule inhibitors that, in contrast with Trastuzumab, display the ability to reach 
the brain. As described above, Src family is critical in HER-2- and 16-driven 
signal transduction. Recently, Zhang and co-workers suggested a Src role in 
promoting brain metastases in breast cancer and they showed that the therapeutic 
combination of Src inhibitor Saracatinib and HER-2/EGFR inhibitor Lapatinib 
was effective in inhibiting experimental HER-2-positive brain metastases in a 
preclinical model (Zhang et al., 2013). Similarly to Saracatinib, other 
combinatorial regimens targeting both HER-2 receptor and signaling effectors, 
including PI3K, could be equally effective and need to be investigated. To address 
this issue, the multiorgan metastasic model described in this thesis seems 
particularly suitable. 
Since the pioneering study of Martuza and colleagues (Martuza et al., 
1991), the therapeutic ability of oncolytic HSV has been evaluated in preclinical 
and clinical studies. For example, NV1020, an attenuated recombinant HSV with 
wild-type tropism, was effective in treating colorectal cancer metastatic to liver in 
a phase II clinical trial (Geevarghese et al., 2010). However, virus attenuation 
generally interfers with its therapeutic potential, and the development of 
engineered viruses with high specificity for tumor cells allows to preserve their 
wild-type replicative activity (Miest and Cattaneo, 2014). Here, the efficacy of a 
HER-2-retargeted HSV (R-LM249) was assessed in Rag2
-/-
;Il2rg
-/-
 mice (Nanni et 
al., 2013). All HER-2-positive human cell lines tested in vitro, including 
Trastuzumab-resistant cells, were sensitive to R-LM249. After the s.c. injection of 
HER-2-positive human breast cancer cells, the virus was able to inhibit tumor 
growth and prolong the life expectancy of mice. Finally, treatment of HER-2-
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positive breast and ovarian advanced cancers in Trastuzumab-resistant models 
successfully inhibited the growth of metastases in the peritoneum and in the brain 
of animals.  
In contrast with other anti-HER-2 agents (i.e. monoclonal antibodies and 
tyrosine kinases inhibitors), R-LM249 efficacy lies on its combined abilities to 
specifically target HER-2 (as well as other agents targeting HER-2 receptor do) 
and kill tumor cells (cytotoxic activity that belongs to viruses). Furthermore, 
contrary to HER-2 inhibitors and monoclonal antibodies, the retargeted virus is 
not dependent on HER-2 signaling and on host’s immune responses (e.g. 
Trastuzumab-triggered ADCC). In addition, it is able to amplify its cytotoxic 
effect replicating into cancer cells, but it exhausts itself when HER-2-positive 
tumor cells are no longer available. 
 If compared to oncolytic HSV previously investigated, R-LM249 was 
designed to target a specific antigen overexpressed only by tumor cells 
(oncoantigen, see below in the Discussion). As a result, it exploits its activity only 
when it reaches HER-2-positive cancer cells, without infecting other sites.  
Due to its systemic delivery route (i.p.), a high safety profile of R-LM249 
was required. In preliminary in vivo experiments conducted by Menotti and 
colleagues the virus did not kill any mouse, even at doses that were much higher 
than those required by wild-type HSV to kill all mice (Menotti et al., 2009). 
Furthermore, the retargeted virus was specific for tumor cells that highly 
expressed HER-2 on plasmatic membrane and it could not revert to the wild-type 
form because of the deletion of a large portion of gD gene (Menotti et al., 2009). 
Nevertheless, specific therapy with acyclovir is available in a worst case scenario 
(Campadelli-Fiume et al., 2011). 
 The reduction in the incidence and in the quantity of brain metastatic 
HER-2-positive cells in Rag
-/-
; Il2rg
-/-
 mice treated with R-LM249 can be 
attributed to its ability to cross the blood-brain barrier. In light of these findings, 
this retargeted virus should be further investigated for anti-HER-2 regimens 
targeting brain metastases in addition to small molecule inhibitors. Furthermore, 
the high-potential use of R-LM249 is even enhanced by the possibility to re-
engineer it in order to target other oncoantigens. 
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In addition to novel anti-HER-2 therapeutic agents, HER-2-targeting 
active immune approaches are under evaluation, exploiting the notion that HER-2 
is a cell surface antigen specifically overexpressed by tumor cells (Lollini et al., 
2013). E75 NeuVax is a nonapeptide derived from the extracellular domain of 
HER-2 protein. As reported by Mittendorf and colleagues (Mittendorf et al., 
2012), the s.c. injection of E75 may stimulate CD8+ cytotoxic T cells and drive 
them to kill HER-2-positive tumor cells. This peptide-based vaccine is currently 
studied in a phase III clinical trial for the adjuvant therapy of HER-2 low-
expressing breast cancers to prevent disease recurrence (Yan et al., 2014).  
In this thesis a whole tumor cell- and a DNA-based vaccine were described 
for the immunoprevention of HER-2-positive breast cancer in a HER-2-tolerant 
model (De Giovanni et al., 2014). The whole-cell vaccine (called HER-2-Cell) 
was developed in the Laboratory of Immunology and Biology of Metastasis 
according to previous studies conducted by the same group of scientists for the 
prevention of Neu-driven carcinogenesis in BalbNeuT mice (Nanni et al., 2001; 
De Giovanni et al., 2004). HER-2-Cell vaccine is composed of three stimuli: a 
human HER-2-positive cell line with blocked proliferative ability (SK-OV-3, 
specific stimulus), the xenogeneic class I molecules of this cell line and murine 
recombinant IL-12 (adjuvant stimuli). HURT-DNA vaccine was developed by 
Quaglino and co-workers and its administration is combined with electroporation 
as adjuvant stimulus (Quaglino et al., 2010).  
As widely described, HER-2 model develops autochthonous mammary 
tumors due to the presence in its genome of 30-50 copies of human HER-2 gene 
and, therefore, HER-2 mice are tolerant towards HER-2. Both vaccines here 
investigated were able to break this tolerance, delaying tumor onset and 
prolonging the life of vaccinated mice. Thus, HER-2-Cell vaccine efficacy is an 
advance of the results obtained by Nanni and co-workers in 2001 (Nanni et al., 
2001), because it allows to resemble a  more realistic immunological approach 
targeting the human proto-oncogene HER-2, instead of its mutated rat hortologue 
NeuT. Notably, vaccinations schedules were repeated all-life long and after more 
than 80 weeks of age, more than 60% of HURT-DNA vaccinated mice were still 
tumor-free. Focusing on tumor multiplicity, vaccinations were able to reduce the 
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growth of multiple tumors. Conversely, in control mice the number of tumors was  
more than doubled if compared to that of vaccinated animals.  
The anti-tumor activity of anti-HER-2 vaccination lies on both humoral 
and cell-mediated responses. Nanni and co-workers showed that the production of 
anti-HER-2 antibodies (by B cells) and IFN- release (by T helper cells) were able 
to prevent mammary carcinogenesis in vaccinated BalbNeuT mice (Nanni et al., 
2001). In a further study, they crossed BalbNeuT mice with a knockout strain 
lacking IFN- production or with B cells-deficient mice, showing that vaccination 
was not able to protect these animals from the development of mammary tumors. 
Thus, they demonstrated that tumor prevention was dependent on cytokines and 
specific antibodies induction (Nanni et al., 2004). Here, both vaccines elicited in 
general a strong humoral response. However, higher and more stable levels of 
anti-HER-2 antibodies were detected in sera from HURT-DNA vaccinated mice. 
In these animals, most represented isotypes were IgG1, IgG2a and IgG2b, whose 
production by B cells is mediated by T helper cells. The inhibitory effect of anti-
HER-2 antibodies on HER-2-positive mammary tumor cells was confirmed by 
their ability to suppress the activation of HER-2 receptor and of PI3K-AKT 
pathway in MAMBO 89. In vivo, the passive immunization by anti-HER-2 
antibodies produced by HURT-DNA vaccinated mice was effective in inhibiting 
the growth of HER-2-positive peritoneal masses in Rag2
-/-
;Il2rg
-/- 
mice, despite 
the absence of most cellular and cytokine responses. Immunodeficient mice were 
chosen to avoid any possible additive immunologic anti-tumor activity by the host 
and, thus, to evaluate the real contribution of anti-HER-2 antibodies alone. 
 Focusing on cell-mediated response, only HER-2-Cell vaccine determined 
the production of IFN- in HER-2 mice, confirming the results obtained with the 
cell vaccine developed by Nanni and colleagues in 2001. IFN- release by T 
helper cells was suggested to mediate anti-tumor efficacy and IgG2a production in 
BalbNeuT mice (Nanni et al., 2001). Thus, the low levels of IFN- released in 
HURT-DNA vaccinated mice suggested that  the high humoral response induced 
by HURT plasmid was sufficient to prevent and delay tumor onset in HER-2 
mice.
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In this thesis the contribution of HER-2 and 16 to mammary 
carcinogenesis was investigated in a model transgenic for both genes (F1 model). 
A dominant role of 16, especially in early stages of tumorigenesis, was 
suggested and the coexistence of heterogeneous levels of HER-2 and 16 in F1 
tumors revealed the undeniable value of F1 strain as preclinical model of HER-2-
positive breast cancer, closer resembling the human situation in respect to 
previous models. 
The therapeutical efficacy of anti-HER-2 agents, targeting HER-2 receptor 
(Trastuzumab, Lapatinib, R-LM249) or signaling effectors (Dasatinib, UO126, 
NVP-BKM120), was investigated in models of local or advanced HER-2-positive 
breast cancer. In contrast with early studies, data herein collected suggested that 
the presence of 16 can predict a better response to Trastuzumab and other agents 
targeting HER-2 receptor or Src activity. Using a multiorgan HER-2-positive 
metastatic model, the efficacy of NVP-BKM120 (PI3K inhibitor) in blocking the 
growth of brain metastases and the oncolytic ability of R-LM249 (HER-2-
retargeted HSV) to reach and destroy metastatic HER-2-positive cancer cells were 
shown. 
Finally, exploiting the definition of “oncoantigen” given to HER-2, the 
immunopreventive activity of two vaccines on HER-2-positive mammary 
tumorigenesis was demonstrated.  
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